ABSTRACT
Adaptor proteins are specialized protein binding partners that serve to link signaling proteins to each other, as a mechanism to propagate a cellular signal. Ultimately, these signals are required for a specific biological response. Thus, it is important that the cell develop mechanisms to regulate these signaling cascades. One way these cascades can be regulated is through post translational modifications of adaptor proteins which would regulate their ability to forge protein-protein interactions. In this review, we summarize the effects of serine/threonine and tyrosine phosphorylation on adaptor protein function, with a specific focus upon those adaptor proteins in which phosphorylation has been demonstrated to regulate a signaling cascade or biological response.
INTRODUCTION
Adaptor proteins are defined as intracellular proteins that contain modular domains capable of recruiting additional signaling molecules, but exhibit no enzymatic activity (1) . These proteins function by linking signaling molecules in such a way as to propagate a cellular signal, resulting in a biological outcome. Biological responses must be regulated and adaptor protein interactions with appropriate binding partners are also regulated, e.g., by changes in cellular localization that permit approximation to binding partners, changes in steady-state expression levels and through post translational modifications. It is the latter that is the subject of this review. Specifically, we will focus on the role of phosphorylations in modulating the activity of adaptor proteins and their ability to interact with cellular binding partners.
We consider that phosphorylation could modulate adaptor protein function in 4 significant ways ( Figure 1 ).
Here, phosphorylation could (a) alter the conformation of the adaptor protein, which in turn would alter its ability to interact with binding partners, (b) create a protein binding motif, (c) through known protein binding modules such as SH2 or PTB, enable a protein to seek out and bind to a phosphorylated binding partner, or (d) alter the properties of an adaptor protein enabling it to impede or block the progression of signals in a signaling pathway. There are two types of phosphorylation events to cover in eukaryotes -serine/threonine and tyrosine phosphorylation. In this review, we attempt to comprehensively cover how phosphorylation events alter the function of adaptor proteins. We initiate this review with the effects of tyrosine phosphorylation on adaptor protein function, then segue into the well studied signaling cascades associated with T cell and B cell signaling that are dependent upon the function of several adaptor proteins. Finally, we discuss the role of serine/threonine phosphorylation in regulating adaptor protein function. Each of these two topics are covered within the context of the 4 ways we envision phosphorylation effecting the function of adaptor proteins. We acknowledge that phosphorylation may alter adaptor protein function in ways that we have not envisioned; however, for simplicity, we group these effects of phosphorylation into these 4 main categories.
Tyrosine phosphorylation plays an important role in the function and regulation of several adaptor proteins. Many adaptor proteins contain either a modular protein binding domain for mediating protein interactions with phosphorylated substrates, tyrosine residues that, upon phosphorylation, recruit in binding partners with modular binding domains, or both. Two modular domains that are important in modulating adaptor protein function are the SH2 domain and the PTB domain. The Src homology 2 (SH2) domain is a globular protein interaction module that directs protein-protein interactions (2, 3, 4, 5) . Proteins containing these domains are involved in the control of biochemical pathways involving phospholipids metabolism, activation of Ras-like GTPases, gene expression, protein trafficking, tyrosine phosphorylation and dephosphorylation, and cytoskeletal rearrangements (3) . SH2 domains bind to relatively conserved sequences Table1. Signaling proteins that are involved in cellular signaling cascades of a phosphorylated tyrosine residue followed by specific residues (usually at position +2 to +5) that dictate binding specificity (6) , and have relatively no affinity for unphosphorylated peptides (3) . Binding of phosphorylated SH2-binding motifs to the SH2 domain can affect its function in several ways, including the direct stimulation of enzymatic activity, enhanced tyrosine phosphorylation, and relocalization of the protein to a different sub-cellular site (3) . The phosphotyrosine-binding domain (PTB) is similar to the SH2 domain in that both domains recognize phosphorylated tyrosine consensus sequences. However, PTB domains recognize amino acids that are located amino terminal to the phosphotyrosine-binding pocket, and these residues are essential for determining PTB-binding specificity. Table 1 summarizes several adaptor proteins that are substrates for tyrosine phosphorylation and become binding partners for signaling proteins that contain SH2 and/or PTB domains, as well as SH2 and PTB domaincontaining proteins. We summarize the effects of tyrosine phosphorylation on adaptor proteins where phosphorylation is known to affect function.
ADAPTOR PROTEINS THAT UNDERGO A CONFORMATIONAL CHANGE IN RESPONSE TO TYROSINE PHOSPHORYLATION

Crk/CRKL
Crk (chicken tumour virus no. 10 regulator of kinase) was first identified as a fusion gene (v-Crk) of the viral gag gene and a cellular gene that, when transfected into chicken embryo fibroblasts, leads to the activation of cellular tyrosine kinases and the expression of a transformed phenotype (7) . Crk is expressed as two distinct proteins of 28 (Crk-I) and 40 kDa (Crk-II) (8) . Both of the Crk proteins contain an SH3 domain and an SH2 domain mediating protein-protein interactions important in the assembly of multimeric signaling complexes (8) . Crk is homologous to the CRKL (Crk-like) protein; however, they originate from different genes (6) . Crk-II and CRKL contain a tyrosine residue at position Y221 (Y207 in CRKL) that is absent in Crk-I, and the sequence surrounding Y221 represents the major tyrosine phosphorylation site in Bcr-Abl expressing B cells (9) . Feller et al. (10) predicted that phosphorylation of Y221 resulted in the ability of c-Crk-II to bind to its own SH2 domain, blocking access of its SH3 domain from binding other proteins. Several studies have looked into the regulation of Crk signaling by folding (11, 12, 13, 14, 15, 16, 17, 18) and their results support the inhibitory role of pY221 in Crk signaling. However, many of these studies used cell lines expressing high levels of protein and receptors, and may not be reflective of true in vivo conditions (6) .
Alternately, Crk and CRKL do have highly homologous SH2 domains, and appear to have similar SH2-directed binding specificities, as many of the SH2 protein-binding partners of Crk have also been shown to co-immunoprecipitate with CRKL (19). The SH2 domains of Crk/CRKL have been shown to interact with phosphorylated tyrosine residues in Cbl, STAT5, p85 PI3K, Gab2, p62dok, IRS1/4, FRS2, p130Cas, ZAP-70, and paxillin in response to a number of cellular stimuli, including T cell, B cell, cytokine, hormone, and growth factor receptor engagement (20, 21, 22, 6, 23) . One attractive hypothesis is that upon receptor activation, Crk becomes tyrosine phosphorylated on Y221, resulting in a conformational change that blocks access of the SH3 domain from other adaptor proteins, effectively desensitizing the Crk signaling pathway (6) . Recently, Guris and colleagues were able to develop a Crk-deficient mouse model containing a targeted disruption in the crkl gene (24). These mice show severe defects in neural crest development, which mimics the phenotype of mice with DiGeorge syndrome. Individuals with this phenotype rarely survive until birth. Tissues and organs that depend on neural crest cells for development (thymus, thyroid, parathyroid, and head skeletal structures) were also affected. There is no mouse model to date with a targeted disruption of the crk gene (6) . These data position Crk and CRKL as an essential adaptor protein, important in embryonic development.
Vav
The Vav family of proteins currently consists of three members: Vav, Vav2 and Vav3. The protein domain structure of Vav is diverse, containing a calponinhomology (CH) domain, an acidic region, a Dbl-and pleckstrin-homology domain (DH and PH), as well as an SH2 domain flanked by two SH3 domains (25). The most characterized role of Vav proteins is their activity as guanosine nucleotide exchange factors for Rho/Rac proteins (26, 27, 28, 29) . Vav enzyme activity catalyzes the release of GDP from inactive GTPases, favoring the binding of GTP and the concomitant change in protein conformation that allows the active GTPases to bind their specific substrate (30). The catalytic activity of Vav is modulated by tyrosine phosphorylation, which is specific to Vav (26, 27, 28, 29) . In the unphosphorylated state, tyrosine 174 contacts residues in the Rac1 binding site of the catalytic domain, directing the formation of a closed protein conformation. In this conformation, Vav is unable to interact with substrate (31). Tyrosine phosphorylation of Y174 causes a steric clash between the phosphate group and several residues present in the DH domain of Vav, resulting in an open protein conformation that is capable of binding Rac1 (31). It is possible that other residues in the amino terminal portion of Vav also contribute to its autoinhibitory state, and in accordance with this theory, deletions in the amino terminal CH domain result in the oncogenic activation of Vav, even when the acidic domain and the inhibitory Y174 are present (32, 29 Because BLNK is highly homologous to Slp-76, it is likely that these pathways are conserved in B cells as well (25). Vav can also complex with other SH2 domain-containing proteins including Shc and p85 PI3K; however, the role of these associations have not been elucidated (28,51,25).
ADAPTOR PROTEINS THAT CONTAIN MODULAR DOMAINS THAT RECRUIT BINDING PARTNERS
Shc
Shc is a prototype adaptor protein that has been useful in the understanding of adaptor protein function in cellular signaling cascades (52) . To date, three shc genes have been identified, and their protein products, ShcA, ShcB, and ShcC, appear to have a conserved protein domain structure (53, 54) .
In mammals, ShcA is ubiquitously expressed, while ShcB and ShcC appear to be found only in neuronal cells (54, 55) . ShcA can be further classified into three different isoforms of 46, 52, and 66 kDa (56, 57) . All of the Shc isoforms contain both an SH2 domain and a phosphotyrosine-binding (PTB) domain separated by a central linker region with several essential tyrosine phosphorylation sites (54) .
The main function associated with Shc is the recruitment and binding of specific signaling molecules into larger complexes, thereby linking cell surface receptor stimulation to downstream effector molecules. Earlier studies indicated that the SH2 domain of Shc appeared to be important for the recruitment of Shc to cell surface receptors, including EGFR, PDGFR, and the TCR-ζ chain (57, 58, 59, 60) . However, the SH2 domain alone is not responsible for Shc localization to the TrkA receptor or the polyoma middle T antigen (61, 62) . Further investigation led to the discovery of an amino-terminal PTB domain in Shc, capable of binding phosphorylated tyrosine residues N-terminal to the pY (63, 64, 65, 66, 67, 68) . The PTB domain of Shc has been reported to bind to several tyrosine-phosphorylated proteins, such as EGFR, NGFR, the insulin receptor (69, 68, 63, 70) , and also acidic phospholipids like PI and PIP3 (67, 71, 72) .
The CH1 (collagen homology 1) domain of p52Shc contains three critical tyrosine residues (Y239, Y240, and Y317) that become phosphorylated in response to a variety of signals, including a growth factor and cytokine receptor stimulation, integrin engagement, and Gprotein coupled receptor engagement (73, 53, 52) . Mutation of Y317 alone or Y239/Y240/Y317 combined results in a dominant negative effect in Shc signaling (74, 75, 76, 77, 78, 79, 52) . Tyrosine phosphorylation of these sites in the CH1 domain creates binding sites for the SH2 domain of Grb2. Grb2, in turn, binds to the Ras nucleotide exchange factor Sos, localizing this complex to the membrane and directing the subsequent activation of the Ras/MAPK pathway (52) . Shc has also been implicated in the regulation of c-Myc activation (74) , neuronal cell survival (55) , and focal adhesion and cytoskeletal organization (80,81). In hematopoietic cells, ShcA has been shown to bind to SHIP1 and SHIP2, potent negativeregulators of cytokine signaling (82). However, the functional implication of this interaction in cell signaling events is not clear.
Hyperphosphorylation of Shc has been observed in many different tumors (83,84,85), and a knockout of the shcA gene results in embryonic lethality at day 11.5 (86). These data suggest that Shc is an essential adaptor protein that functions in almost every aspect of cell growth and differentiation, including embryonic development.
Grb2
Grb2 is a ubiquitously expressed adaptor protein that functions in coupling growth factor receptor engagement with Ras activation (87,1). The protein structure of Grb2 contains an SH2 domain flanked by two SH3 domains, and these regions mediate interactions between activated receptors and downstream signaling molecules (87, 88, 89, 90, 91, 58) .
Several studies have examined the role of Grb2 in linking tyrosine kinase receptors to downstream effector pathways. The SH2 domain of Grb2 is recruited to activated growth factor receptors, the TCR or the BCR either directly or indirectly through complex formation with Shc (92). The SH3 domain of Grb2 interacts with several binding partners, effectively positioning signaling molecules in the proximity of activating kinases. Grb2 is also able to interact with Sos, a Ras guanosine nucleotide exchange factor, via its SH3 domain. Membrane localization of the Grb2/Sos complex facilitates the interaction of Sos with its substrate Ras, leading to the activation of the Ras/MAPK pathway. In conclusion, Grb2 appears to function as an adaptor protein that couples receptor activation to downstream signaling effects in both lymphoid and non-lymphoid cells. The role of Grb2 in immune cell signaling pathways will be discussed later in this review.
Nck/Dock
The Nck/Dock is an SH2/SH3 adaptor protein family that plays an important role in signaling pathways that lead to alterations in the actin cytoskeleton (93). The Nck family is comprised of Nck-alpha/Nck/Nck1 and Nckbeta/Grb4/Nck2 (93). The protein domain structure of Nck reveals one SH2 domain and three SH3 domains important in connecting upstream signals to specific downstream pathways (94).
Studies by Chou (95), Li (96), Meisenhelder and Hunter (97), and Park and Rhee (98) demonstrated that Nck is tyrosine phosphorylated in cells in response to growth factor receptor engagement (EGFR, PDGFR, and Eph1/ELK) or transformation by Src. However, the functional significance of these phosphorylations remains unclear (93). Also, these studies suggested that Nck was able to interact directly with RTKs, and this interaction was dependent upon the Nck SH2 domain. While Nck possesses the ability to bind to several RTKs, a handful other proteins have been identified as SH2 binding partners in many receptor-activated pathways. Among these are p130Cas, Dok-1, IRS-1, HPK1, SLP-76 (in T cells), and BLNK (in B cells) (93,99). Nck also mediates a large number of protein interactions via its three SH3 domains. The main function associated with the adaptor protein Nck is to link cell surface receptors to the actin cytoskeleton through its protein binding domains (94). The role of Nck in immune cell signaling pathways will be discussed later in this paper.
ADAPTOR PROTEINS THAT CONTAIN BOTH MODULAR DOMAINS AND TYROSINE RESIDUES
Cbl
The c-Cbl protooncogene was first identified as the cellular form of the transforming retroviral protein vCbl (100,101). c-Cbl is a 906 amino acid protein that is ubiquitously expressed in mammalian cells (101), including the thymus, spleen, testis, lung, brain, heart, and cells of hematopoietic origin. Extensive research on Cbl resulted in the discovery of additional Cbl family members Cbl-b, which is also ubiquitously expressed, and Cbl-3/Cbl-c, which is expressed primarily in the gastrointestinal system (102). Structural analysis of the Cbl family proteins reveals several protein binding domains, including a highly conserved N-terminal domain composed of a zinc-binding RING finger domain, a calcium-binding EF hand domain, and a modified SH2 domain (103). The N-terminal region of Cbl is responsible for binding phosphorylated tyrosine residues of multiple protein tyrosine kinases, and is also referred to as the tyrosine kinase-binding (TKB) domain (104, 105, 106 In addition to participating in signaling pathways that positively regulate cellular functions, Cbl has also been implicated in the negative regulation of growth factor receptors and in T cell anergy. In the role of a negative regulator, Cbl proteins have emerged as mediators of ubiquitination of certain growth factor receptors, including EGF, PDGF, and CSF-1 (117,118,119,120). Within the amino terminus of Cbl is a zinc-binding RING finger motif that is associated with E3 ubiquitin-ligase activity. An E3 ubiquitin ligase recognizes phosphorylated tyrosine substrates and recruits E2 ubiquitin-conjugating enzymes through its RING domain (121,122,123). E2 and E3 work in conjunction to transfer ubiquitin to substrate proteins, targeting these substrates for degradation by the proteosome (102). Several studies have highlighted the importance of PTB-mediated interactions with target PTKs for Cbl-dependent ubiquitination. A mutant of Cbl that lacks its C terminus is still able to bind to Syk, Zap-70, EGF, and PDGF receptors (104,124,105,106,125,126). Also, a decrease in binding between Cbl and PTKs caused by an inactivation of the SH2-like domain results in a significant inhibition in tyrosine phosphorylation of Cbl (127,126), and abrogates Cbl-mediated ubiquitination of these receptors (128,127). In another experiment, the expression of a protein fragment encompassing the PTB and RING domains of Cbl was sufficient for ubiquitinationmediated desensitization of the EGF receptor (122,128). Growth factor receptors are not the only targets of Cblmediated ubiquitination. Syk, Fyn, and various receptors without enzyme activity have also been identified as Cbl targets, although in some cases, the PTB domain does not facilitate the binding of Cbl to the target protein (129, 130, 131) . Through the ability of Cbl to mediate protein degradation, a possible biological function for this protein could be the negative regulation of constitutively active PTKs that are identified to be the cause of certain oncogenic transformations (102).
FRS2/SNT
The nerve growth factor receptor (NGFR) and the fibroblast growth factor receptor (FGFR) belong to a large group of receptor tyrosines kinases that regulate cell growth, differentiation, and survival (132, 133) . Both the FGF and NGF receptors contain an extra-cellular ligand binding domain, a transmembrane region, a protein tyrosine kinase domain, and several tyrosine residues that serve as recognition domains upon phosphorylation (134, 135) . Activation of these RPTKs has been implicated in the stimulation of the Ras/MAPK signaling cascade via the recruitment of Grb2/Sos (136, 137, 135) . However, both the NGF and FGF receptors lack the SH2-consensus binding sequence of Grb2, and must use a different, indirect method to recruit the Grb2/Sos complex to the plasma membrane (138) .
The FRS2 protein family (FGF receptor substrate 1, also known as SNT1 (suc1-associated neurotrophic factor target protein)) is composed of the highly homologous FRS2-alpha and FRS2-beta isoforms (136, 138) , and these proteins serve as essential mediators of downstream signals emanating from the FGF and NGF receptor, and possibly the Insulin receptor (139) . The protein domain structure of FRS2 reveals an N-terminal myristylation signal, a PTB domain, and a C-terminal region with several tyrosine residues that serve as binding sites for SH2 domain-containing proteins upon phosphorylation (138) .
FRS2-alpha is found to be constitutively bound to the FGFR1 via the FRS2 PTB domain. However, this association is not dependent upon receptor tyrosine phosphorylation. Alternatively, the PTB domain of FRS2-alpha and FRS2-beta bind to the NGF receptor TrkA in a tyrosine phosphorylation-dependent manner (140, 141) .
Both NGF and FGF receptor stimulation results in the phosphorylation of five tyrosine residues in FRS2 (142) . Four of these phosphorylated tyrosine residues (Y196, Y306, Y349, and Y392) serve as binding sites for the recruitment of Grb2/Sos complexes, while the fifth residue (Y436) binds to molecules of SHP2 (136, 142, 143) . FRS2 interaction with SHP2 results in its own tyrosine phosphorylation, leading to the recruitment of and complex formation with other Grb2 molecules. The ability of FRS2 to recruit Grb2/Sos complexes both directly and indirectly positions FRS2 to act as a mediator of Ras/MAPK pathways in response to growth factor receptor signaling (142, 136) . Evidence for the role of FRS2 in Ras/MAPK activation arises from studies that utilize mutants of FRS2 that are unable to bind SHP2 and/or Grb2. Overexpression of the SHP2-binding mutant or the Grb2-binding mutant resulted in the induction of MAPK activity, but this activity was not sustained (142) . Overexpression of the FRS2/Grb2 binding mutant resulted in a very weak induction of FGF-induced MAPK activation and a loss in neurite outgrowth in PC12 cells (142, 136) , indicating that FRS2 binding to both of these signaling molecules is important in the FGFR1-mediated activation of the MAPK pathway.
It was also demonstrated that FRS2 plays a role in the FGF-induced recruitment and tyrosine phosphorylation of Gab1 (144) . Binding of the SH2 domain of Grb2 to tyrosine phosphorylated FRS2α mediates the recruitment of Gab1 to Grb2, resulting in FRS2-alpha/Grb2/Gab1 ternary complex formation (144) . Gab1 is then tyrosine phosphorylated by the FGF receptor, creating a binding site for the SH2 domain of the p85 subunit of PI3K. Recently, Hadari et al. (145) introduced a targeted mutation into the frs2α gene, creating FRS2-deficient mice and FRS2α-deficient mouse embryo fibroblasts. These mice showed impaired cell migration, MAPK activation, PI3K activity, and cell proliferation upon induction with FGF. These FRS2-alpha-deficient mouse fibroblasts were used to investigate the role of FRS2-alpha in FGF-mediated PI3K stimulation. Lysates from FGF-stimulated wild type and FRS2-alpha-deficient fibroblasts were examined for Gab1 tyrosine phosphorylation. Phosphorylation of Gab1 on tyrosine was 
Cortactin
Cortactin is a cortical actin binding protein that is involved in RhoGTPase and Src signaling events that regulate changes in actin dynamics (148) . The protein domain structure of cortactin reveals an amino terminal acidic region, a proline-rich region with several tyrosine residues, and an SH3 domain at the carboxy terminus (149, 150) . Cortactin was first identified as a tyrosine phosphorylated protein in Src-transformed cells (151) . Since then, several studies have shown that cortactin is a substrate for Src in response to many extracellular stimuli, including growth factors (FGF and EGF), integrin signaling, and cellular stresses (H 2 O 2 ) (148) . Coimmunoprecipitation studies indicate that Src binds to cortactin directly via its SH2 domain, and subsequent tyrosine phosphorylation of cortactin creates binding sites for other SH2 domain-containing proteins (152, 153, 154) . Okamura and Resh (153) demonstrated that in quiescent cells, cortactin is not tyrosine phosphorylated and is mainly associated with the detergent-soluble fraction. However, in cells expressing v-Src, tyrosine phosphorylation of cortactin by Src leads to a significant increase in cortactin association with the Triton-X insoluble cytoskeletal fraction. These data indicate tyrosine phosphorylation of cortactin serves to localize cortactin to the specific intracellular compartments.
Using Fyn-/-Csk-/-and Src-/-Csk-/-fibroblasts, Thomas et al.(155) showed that Src is the tyrosine kinase primarily responsible for the phosphorylation of cortactin resulting from knockout of the csk gene. Expression of a cortactin mutant with phenylalanine substitutions at Y421, Y466, and Y482 resulted in a dramatic reduction in cortactin tyrosine phosphorylation in v-Src-transformed cells (156) . Huang et al. (156) showed that tyrosine phosphorylation of cortactin by Src resulted in a decrease in the ability of cortactin to cross-link actin filaments. Over-expression of a cortactin mutant that is unable to be phosphorylated by Src showed impaired cell migration, while overexpression of wild type cortactin resulted in an increase in endothelial cell migration. However, the full significance of Src-mediated tyrosine phosphorylation of cortactin has not yet been elucidated (148) .
A second non-receptor tyrosine kinase implicated in cortactin tyrosine phosphorylation in response to growth factor stimulation is Fer (157) . Fer immunoprecipitates with cortactin, and this interaction is thought to be mediated by the Fer SH2 domain (158) . The involvement of Fer in growth factor-mediated cortactin phosphorylation is further supported by the suppression of CSF-1 receptor mediated tyrosine phosphorylation of cortactin by the expression of a kinase dead Fer (158) . Further studies by Kapus et al. (159) indicated that upstream signaling through Fyn is required for Fer mediated tyrosine phosphorylation of cortactin; however, the significance of this phosphorylation event is still unknown (148).
Paxillin
Paxillin is a 68-70 kDa adaptor protein that is thought to function as a scaffold protein in the organization of signaling complexes at focal adhesions (160, 161) , coordinating the transmission of signals that affect cell morphology and motility (162, 163) . A number of motifs have been characterized in paxillin that mediate proteinprotein complex formation, including a N-terminal proline-rich region, several tyrosine residues that are consensus sequences for SH2 domains, an LD motif, and four LIM domains (164, 165) . The LIM domains are thought to facilitate the localization of paxillin to focal adhesions through their interaction with β-integrin tails or possibly though an intermediate adaptor protein (160) . Stimulation of cells with growth factors, neuropeptides, antigens, Gprotein coupled protein receptor ligands, and cellular stresses have all been described to stimulate the tyrosine phosphorylation of paxillin (161) . While paxillin can be phosphorylated in response to a large number of stimuli, only a few tyrosine kinases have been implicated in this process. Focal adhesion kinase (FAK) and the FAK-related protein CAK-beta/Pyk2/CadTK/RAFTK physically associate with paxillin, and the activation of these kinases is associated with tyrosine phosphorylation of paxillin (166, 167) . There is also a role for Src tyrosine kinases in paxillin phosphorylation. Fibroblasts lacking Src, Fyn, and Yes demonstrate dramatic reductions in the phosphorylation state of paxillin, while fibroblasts derived from csk-/-mice exhibit enhanced Src family kinases activity and an equally enhanced increase in paxillin tyrosine phosphorylation (155, 168) .
As tyrosine phosphorylation of paxillin is increased in Abl-transformed 32D cells, paxillin may also serve as a target for the Abl tyrosine kinase as well (165) .
There are four sites of tyrosine phosphorylation in paxillin (possibly five), including Y31, Y118, Y40 and Y88 (169, 170, 162) . The only known function associated with paxillin tyrosine phosphorylation is the creation of binding sites for SH2 domain-containing proteins (161) . The SH2 domain of Crk and CRKL bind to paxillin with high affinity at tyrosines pY31 and pY118 (171, 169, 172) . This enables Crk to bind other proteins like C3G guanine nucleotide exchange factor and Dock180 via SH3 domain binding (173) . Csk and Chk, a Csk-related kinase, have also been reported to bind to phosphorylated paxillin via SH2 domain binding (174, 169, 175, 176) . Likewise, Src can also associate with paxillin, in vitro, and Lck can associate with paxillin in vivo in T cells (169, 177) . Therefore, tyrosine phosphorylation of paxillin serves as an essential step in the recruitment of diverse cytoskeletal and signaling proteins into functional complexes in focal adhesions.
RACKs
The protein kinase C (PKC) family of serine/threonine kinases are important regulators of cellular proliferation, differentiation, and cytoskeletal rearrangements (178) . There are at least ten different PKC isoforms that can be divided into three subfamilies based on their sensitivity to second messengers (179, 180) . It has been evidenced that the activation of PKC isoforms is dependent upon the translocation of each isoform to different sub-cellular compartments, thereby conferring specificity in substrate phosphorylation and subsequent downstream cellular responses (181) . The localization of individual PKC isoforms to specific sub-cellular sites is thought to involve the RACKs family of anchoring proteins (receptor for activated C-kinase). Members of the RACK protein family have been reported to display PKC isozyme selectivity, resulting in the ability of RACK to anchor activated PKCs in close proximity to their physiological substrates (182) . However, RACKs themselves are not substrates for PKC kinase activity (183, 184) . RACKs are composed of seven repeats of the WD40 motif, a domain that is also found in the beta subunit of the heterotrimeric G-protein (185) . WD40 domains are responsible for the recruitment of several PKC substrates, including PLCgamma, RasGAP, and Dynamin-1.
Interestingly, the induction of PKC activity upon treatment with phorbol ester (PMA) resulted in the activation of Src in Swiss 3T3 cells (186). However, the mechanism by which PKC regulates Src activation is poorly understood. Using a yeast two-hybrid system, Chang (187) demonstrated that c-Src can directly bind RACK1, and this binding is increased upon the phosphorylation of a tyrosine residue in the 6 th WD40 domain of RACK1 (182) . The interaction between Src and RACK1 is enhanced by PKC activation, as treatment of CHO cells with PKC activator PMA resulted in an increase in RACK1/Src binding (182) . While it is unclear at this time which tyrosine kinase is responsible for the phosphorylation of RACK, it is tempting to suggest that RACK is a substrate for Src kinase, and this in turn allows for enhanced binding of RACK to the Src-SH2 domain (182) . Overall, RACK appears to serve as a scaffolding protein that is involved in the recruitment and assembly of signaling complexes. Also, due to its ability to both bind and localize PKC and Src, RACK may serve as a novel link between the tyrosine kinase pathway and the serine/threonine kinase pathway.
PECAM-1
PECAM-1 (platelet/endothelial cell adhesion molecule-1) is a 130-kDa cell surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that is abundantly expressed on endothelial cells, platelets, myeloid cells, mast cells, monocytes, and defined T cell subsets (188) . The structure of PECAM-1 is highly conserved across species, and consists of an extracellular segment with six Ig-like domains (C2 type), a transmembrane domain, and a cytoplasmic domain (189) . The cytoplasmic domain contains tyrosine residues and also sequences that resemble dual ITIMs that become phosphorylated in response to a variety of stimuli, including mechanical stimulation of endothelial cells (190) , platelet aggregation (191) , TCR engagement (192) , IgE receptor activation on basophils (192) , and treatment with protein-tyrosine phosphatase (PTP) inhibitors vanadate and pervanadate (193, 194, 191) . Three main functions are attributed to PECAM-1. They include the mediation of leukocyte-endothelial interactions, inter-endothelial cell adhesion, and the transendothelial migration of cells (195, 196) .
Tyrosine phosphorylation of PECAM-1 is thought to be mediated by Src family kinases, as PECAM-1 tyrosine phosphorylation is abolished in cells treated with the Src family inhibitor PP2 (197) . Also, PECAM-1 tyrosine phosphorylation is observed in Cos-1 cells that are transiently co-transfected with c-Src, Csk, Lck, Fyn, and Lyn (189) . These data support the potential role of Csk 
FcγRIIb/CD32 B cells, myeloid cells tyrosine kinases as mediators of PECAM-1 tyrosine phosphorylation. Recently, Newman (198) determined the importance of Lck in PECAM-1 tyrosine phosphorylation in T lymphocytes.
Tyrosine phosphorylation of the cytoplasmic ITIMs in PECAM-1 directs its association with the protein tyrosine phosphatases SHP-1 and SHP-2 (192) . Tyrosines in position 663 and 686 (Y677 and Y700 in murine PECAM-1) of the ITIM sequence were found to be essential for this protein interaction to occur (194) . Mutation of either of these residues reduced PECAM-1 tyrosine phosphorylation to barely detectable levels in PECAM-1-transfected 3T3 cells.
Phosphorylation of tyrosine residues also creates SH2-binding sites for the SH2 domains of Src tyrosine kinases (191, 199, 194) . As is observed with CD22 in B cells, PECAM-1 appears to function as a negative regulator of signaling pathways involved in its own tyrosine phosphorylation.
Recently, several reviews have focused on the importance of adaptor proteins in immune cell signaling events (200, 201, 202, 203) . Several adaptor proteins are expressed only in lymphoid cells where they appear to play a role in connecting cell surface receptors to intracellular effector molecules. Table 3 contains a list of adaptor proteins, their expression patterns, protein-protein binding domains, and associated binding partners. The specific role of tyrosine phosphorylation and tyrosine-mediated protein binding will be discussed for several of these proteins below.
TYROSINE PHOSPHORYLATION REGULATES ADAPTOR PROTEINS THAT PLAY A ROLE IN SIGNALING PATHWAYS IN T LYMPHOCYTES
T cell receptor-mediated signaling is essential for the development and function of T cells as effectors of cellmediated immunity (204) . The T cell receptor (TCR) is composed of a heterodimer of alpha and beta polypeptide chains that are non-covalently linked to an invariant polypeptide complex consisting of CD3 gamma, delta, and epsilon chains and TCR-gamma chains (1) . TCR engagement leads to the activation of Src family kinases, namely Lck and Fyn, which are able to phosphorylate tyrosine-containing immunoreceptor tyrosine-based activation motifs (ITAMs) present in the cytoplasmic tails of the TCR-gamma chain.
ITAMs were originally identified in the cytoplasmic tails of the BCR co-receptor molecules Ig-alpha and Ig-beta, but have since then been observed in accessory chains of the TCR and Fc receptors on mast cells and NK cells. ITAMs are composed of two tyrosine residues separated by 13 amino acids, and have the
Upon receptor ligation, the tyrosine residues in these sequences are phosphorylated by receptor-associated tyrosine kinases, creating docking sites for several SH2-containing proteins. In T cells, the phosphorylation of the cytoplasmic ITAM sequences by Src family kinases allows for the recruitment of a second family of non receptor protein tyrosine kinases, ZAP-70, which binds to the phosphorylated ITAM sequence by virtue of its tandem SH2 repeats (205) . ZAP-70 is subsequently activated through auto/transphosphorylation events (206) .
The activation of Src and ZAP-70 tyrosine kinase family initiates a signaling cascade that results in the activation of several other protein tyrosine kinases (PTKs), including the Tec family. The PTK signaling cascade eventually results in the activation of downstream signaling effectors such as PLC-gamma, which directs the hydrolysis of phosphoinositides, and the activation of the Ras/MAPK pathway. These pathways ultimately result in the upregulation of several transcription factors, including AP-1, NF-AT, and NF-kappaB, known to be important in enhanced gene transcription, cellular proliferation, and differentiation (204) .
Propagation of signals emanating from the TCR involves a number of adaptor proteins expressed only in specific lymphoid cells (207) . The effects of protein domain interactions and tyrosine phosphorylation on the conformation and function of these adaptor proteins will be discussed.
LAT and 3BP2
Two adaptor proteins play an important role in TCR signal transduction are linker for activated T cells (LAT) and SH2-domain containing leukocyte protein of 76 kDa (SLP-76). LAT is a type III transmembrane protein that is localized in glycolipid-enriched microdomains (GEMs) due to two palmitoylated cysteine residues (208) , and localization of LAT to GEMs is required for TCR signaling. The intracellular domain of LAT contains multiple tyrosine-based residues that become phosphorylated by ZAP-70 upon receptor ligation (1). Deckert et al. were able to link the adaptor protein 3BP2 to ZAP-70-mediated activation of LAT. 3BP2 is an 80kDa protein that contains an SH2 motif and is only expressed in lymphocytes (209) . 3BP2 interacts with members of the Syk kinase family and LAT via SH2 domain interactions, although not simultaneously. LAT contains two-YEN (Tyr-Glu-Asn) sites that, upon phosphorylation, may function as a binding site for the 3BP2 SH2 domain (210, 209) . As it is still unknown how LAT is recruited to the TCR upon receptor ligation, it is possible that through interactions with LAT, 3BP2 is able to recruit LAT to the activated TCR and the associated tyrosine kinases, resulting in the phosphorylation and activation of LAT. The ability of 3BP2 to associate with both of these proteins provides a mechanism for the activation of LAT by Syk kinases upon TCR activation.
The phosphorylated tyrosine residues in LAT serve as docking sites for several other proteins that contain SH2 domains, including Grb2, Grap, GADS, p85 subunit of PI3K, and PLC-gamma (1, 205) . LAT is also able to recruit several proteins indirectly via linker proteins, including SLP-76 and Vav (211) . The function of LAT tyrosine phosphorylation is thought to involve the re-localization of specific signaling proteins to the plasma membrane, placing them in direct proximity of lymphocytic tyrosine kinases (211) . This would facilitate tyrosine phosphorylation of these downstream molecules that are important in achieving the cellular response.
For example, the recruitment of Grb2 and/or Grap in complex with Sos provides a mechanism for the stimulation of the Ras/MAPK pathway, as does the recruitment and activation of PLC-gamma (212) . The Ras/MAPK signaling pathway culminates in the activation of several transcription factors, including AP-1 and NF-AT (211).
Tyrosine phosphorylation plays an essential role in LAT complex formation and the ability of LAT to activate downstream signaling pathways. Mutation of LAT tyrosines at position 171 and 191 to phenylalanines has a dominant negative effect on TCR signaling, as these mutants can block activation of NF-AT and AP-1 transcription factors (1). Studies using LAT-deficient cell lines and LAT knockout mice emphasize the importance of LAT in TCR signaling. Using the LAT-deficient J.CaM2 Jurkat cell line (42), it was determined that in the absence of LAT, Cbl was hyperphosphorylated on tyrosine, while PLC-gamma1, Vav, and SLP-76 were hypophosphorylated (211) . In agreement with these findings, cell lines deficient in LAT no longer mobilize calcium, do not activate the Ras pathway in response to TCR stimulation, and are defective in NF-AT activity (42, 49, 212) . LAT-deficient mice have a block in thymocyte development at the double negative stage (CD25+CD44-), and these mice have few mature peripheral T cells (213) . The phenotype of these mice is similar to the phenotype observed in Lck, Fyn, ZAP-70, and RAG 1 (-/-) knock out mice (1, 214) . In conclusion, LAT acts a downstream effector molecule of TCR-related kinases, and LAT phosphorylation facilitates the phosphorylation of substrates and the construction of larger signaling complexes capable of regulating TCR-mediated cellular maturation and activation (205).
SIT and TRIM
SIT (SHP-2-interacting transmembrane adaptor protein) is a disulfide-linked homodimeric transmembrane glycoprotein that is expressed in T cells, thymocytes, and, to a smaller extent, in B cells (215) . SIT contains five potential tyrosine phosphorylation sites, one of which is an immunoreceptor tyrosine-based inhibitory motif (ITIM). ITIMs are found in the cytoplasmic tails of several cell surface receptors that modulate activation signals in both B and T lymphocytes. The ITIM consists of the restricted consensus sequence (I/V)-X-Y-X-X-(L/V), and functions in the recruitment of inhibitory phosphatases, such as SHP1 and/or SHIP, to the receptor (216) .
Upon TCR ligation, SIT becomes tyrosine phosphorylated by Src family kinases, most notably Fyn (215) , and Syk kinase. Marie-Cardine et al. (215) proposed a two-step activation model for SIT, requiring input from both Syk and Src kinases. Upon TCR activation, SIT is phosphorylated by a Src PTK, inducing a conformational change in SIT that exposes specific tyrosine residues that can then be phosphorylated by Syk PTKs. However, further experiments are needed to determine the accuracy of this model. Nevertheless, tyrosine phosphorylation of SIT generates binding sites for proteins with SH2 domains. The adaptor protein Grb2 was found to bind to the Y90 and Y188 sequence motifs of SIT via its SH2 domain (217) . SHP-2 protein phosphatase also inducibly associates with Y148 of activated SIT, suggesting that SIT may play a role in the negative regulation of TCR activation (201, 215) . SIT activation is also reported to negatively regulate TCRmediated NF-AT activity (215) , and the ability of SIT to mediate negative regulatory effects is dependent upon its phosphorylation state (217) . It is hypothesized that SIT may bind to Csk, and this interaction results in the negative regulation of NF-AT activity in TCR-mediated signaling (217) . In conclusion, SIT represents a transmembrane adaptor protein that has the ability to regulate signaling downstream of the TCR due to protein-protein interactions.
TRIM (T cell receptor-interacting molecule) is a type III transmembrane adaptor protein, similar to LAT, that is exclusively expressed in T cells and NK cells (218).
TRIM is found to be associated with the ζchain of the TCR complex, and overexpression of TRIM in cells results in a two-fold increase in the expression of TCR/CD3 complex on the cell surface and an increase in calcium mobilization (219) .
Overexpression of TRIM also inhibits the spontaneous internalization of the TCR/CD3 complex, suggesting that TRIM plays a role in the stabilization of the TCR/CD3 complex on the cell surface (219).
The cytoplasmic tail of TRIM contains eight tyrosine residues, three of which are components of a sequence motif that directs interactions with SH2 domain-containing proteins (218) .
Upon TCR engagement, TRIM is phosphorylated by Src family members Lck and Fyn, but not ZAP-70 or Syk (218) . This is evidenced by the fact that identical levels of tyrosine phosphorylation of TRIM are detected in wild type Jurkat cells and in Jurkat cells that are deficient in both Syk and ZAP-70. Also, treatment of cells with the Src inhibitor PP1 completely inhibited tyrosine phosphorylation of TRIM (218) . Tyrosine phosphorylation of TRIM creates an SH2 binding motif for the recruitment of PI3K and two unknown polypeptides of 43 and 50 kDa (217, 219) . However, the role of tyrosine phosphorylation of TRIM in T cell-mediated signaling remains unknown.
SLP-76 and SLAP-130
Another downstream target of ZAP-70 is SLP-76, an adaptor protein whose expression is restricted to cells of hematopoietic origin (220, 47, 1) . SLP-76 contains an SH2 motif and several tyrosine-based residues that become phosphorylated in response to TCR engagement by Syk family PTKs (220, 47 (222) . Mutation of tyrosines in positions 113 and 128 to phenylalanine dramatically decreases SLP-76 tyrosine phosphorylation and the ability of SLP-76 to augment NF-AT activity after TCR ligation (1) . Also, mutation of either tyrosine 113 or 128 to phenylalanine blocks the interaction of SLP-76 and Vav, indicating that these tyrosine residues are important in Vav recruitment to phosphorylated SLP-76 (223) . Similar to LAT, cell lines and mouse models deficient in SLP-76 have been essential in determining the role of tyrosine phosphorylation. SLP-76 gene knockout mice display a phenotype that is identical to LAT-deficient mice, and these mice frequently succumb to severe systemic hemorrhage at an early perinatal stage (224, 225) . J14 is a mutant Jurkat T cell line deficient in SLP-76 that has been used in several experiments to determine the function of SLP-76 in T cell signaling (49) . While tyrosine phosphorylation levels of Vav, ZAP-70, Itk, and LAT were normal in these cells, tyrosine phosphorylation of PLC-gamma1 was almost completely ablated (211) . This would indicate that SLP-76 is an important upstream effector in TCR-mediated PLCgamma1 activation.
Also, TCR-dependent gene transcription mediated by NF-AT was absent in J14 cells, and the re-expression of SLP-76 in these cells resulted in normal NF-AT activity (211) . Recently, Yablonski et al. (226) reported that SLP-76 interacts with PLC-gamma via SH3 interactions, and this interaction is required for downstream activation of Erk, PLC-gamma1, and NF-AT. Therefore, it is proposed that TCR-mediated activation of PLC-γ requires a functional complex of LAT, Gads, SLP-76, and PLC-gamma, as both LAT and SLP-76 appear to be required for PLC-gamma activation in TCR-mediated signaling. Over all, SLP-76 appears to play a role in the recruitment of Vav, Nck, and other essential signaling proteins to the plasma membrane to facilitate their activation. These effector proteins subsequently transduce signals that are required for T cell-mediated immune responses.
GADS/GrpL and Grap
Gads/GrpL (Grb2-related adaptor downstream of Shc) is a Grb2/Grap-related adaptor protein that is specifically expressed in hematopoietic cells that links LAT with SLP-76. Gads is a member of the Grb2 family of adaptor proteins, and contains an SH2 binding motif, and two SH3 binding motifs (227) . Gads was originally isolated as an SH2 binding partner for phosphorylated Shc in K562 leukemic cells, but this interaction has never been demonstrated in activated Jurkat T cells (227) . In T cell, Gads is found to be constitutively associated with SLP-76 via SH3 interactions (228) , and is recruited to LAT via its SH2 domain binding to tyrosine phosphorylated sites in LAT upon TCR activation (229, 207, 228) . Unlike SLP-76 and LAT-deficient mice, mice deficient in Gads exhibit a less severe phenotype, characterized by the presence of double negative and single positive thymocytes (221) . These data indicate that not all SLP-76 dependent functions require Gads. In conclusion, Gads is an essential protein that facilitates crosstalk between LAT and SLP-76 signaling complexes, and provides the link between LAT and SLP-76 required for PLC-gamma activation and subsequent Ras/MAPK activation and calcium mobilization (228, 221) .
Grap (Grb2-related adaptor protein) is another member of the Grb2 adaptor protein family that is specifically expressed in spleen, thymus, and peripheral blood leukocytes (202, 92) . Grap, like Grb2 and Gads, contains an SH2 domain and two SH3 domains that direct interactions with other signaling molecules. Upon TCR ligation in Jurkat cells, Grap interacts with tyrosine phosphorylated Shc and p36/38 via SH2 interactions (1). Like Gads, Grap appears to function as an adaptor protein, mediating protein-protein interactions with specific binding partners in response to TCR activation.
TYROSINE PHOSPHORYLATION REGULATES ADAPTOR PROTEINS THAT PLAY A ROLE IN SIGNALING PATHWAYS IN B LYMPHOCYTES
B-cell receptor-mediated signaling is essential for the development and maintenance of a functional humoral immune response. Recently, new evidence has suggested that the BCR has a role in dual signaling. In the absence of antigen, it participates in the transduction of maintenance signals required for the development and survival of mature B-lymphocytes. Upon antigen binding, the BCR also regulates the activation of B-lymphocytes either for cell death or clonal expansion (230) . The BCR consists of a transmembrane immunoglobulin molecule that is associated with the invariant Ig-alpha and Ig-beta chains in a non-covalent complex. As in TCR engagement, antigen binding to the BCR results in receptor aggregation and activation of non-receptor tyrosine kinases, such as Lyn, Src, Btk, and Syk, which phosphorylate ITAM sequences on the cytoplasmic tails of the BCR co-receptors Ig-alpha and Ig-beta. These tyrosine kinases co-localize with the activated receptor and facilitate the phosphorylation of several adaptor proteins essential in BCR signal transduction. Signals emanating from the BCR ultimately initiate pathways involved in phosphoinositide metabolite regulation, activation of Ras/MAPK pathway, elevation of calcium levels, and the initiation of gene transcription (200).
CD19
Similar to TCR signaling, BCR signaling also requires adaptor proteins that link receptor associated tyrosine kinases to downstream signaling molecules. CD19 is a transmembrane linker protein that is physically associated with the BCR (200) , and has been implicated as a signaling partner for several other B cell surface receptors including CD40 (231), CD38 (232), CD72 (231) , and VLA-4 (233) . Upon receptor engagement, the cytoplasmic tail of CD19 becomes tyrosine phosphorylated by activated Lyn. This phosphorylation event provides binding sites for SH2 domain-containing proteins like Vav and PI3K. In this manner, CD19 functions to localize Vav and PI3K to the plasma membrane in close proximity to the activated BCR. Vav is then tyrosine phosphorylated by receptor associated tyrosine kinases, activating its Rho-GTPase function (26) and initiating a signaling cascade that results in the activation of MAPK/Erk pathway, JNK pathway, and increased calcium mobilization (37,36,234,40). Evidence of the involvement of CD19 in Vav activation comes from experiments using CD19-/-B cells, which display attenuated tyrosine phosphorylation of Vav (235, 200) . Also, CD19-/-mice show reduced B-cell lymphopoiesis and antibody responses to T-cell dependent antigens (236, 237) , indicating that CD19 may play a role in B cell activation and selection (238) . Alternatively, the binding of PI3K to CD19 facilitates its activation, resulting in activation of Btk, which is involved in directing calcium flux, and Akt, which promotes cellular survival (239,240,241,242).
CD22 and FcγRIIb
While BCR-mediated signaling is essential for B cell maintenance and maturation, it is essential to have a mechanism of negative regulation.
CD22 and FcgammaRIIb are two transmembrane linker proteins that are involved in the attenuation of BCR signaling. Both of these proteins contain ITIMs in their cytoplasmic tails, which function as binding sites for SH2 domain-containing phosphatases (243, 244) . CD22 also contains ITAM-like sequences, positioning this adaptor protein to be involved in both the positive and negative regulation of BCRmediated signaling (245, 246, 247) .
In response to BCR activation, Lyn phosphorylates the ITIM of CD22, and this phosphorylation event provides a docking site for the SH2 domain-containing tyrosine phosphatase SHP1. The recruitment of SHP1 to the BCR results in phosphatase activation and the dephosphorylation of a number of proteins including Lyn and Syk. SHP1 activation has also been implicated in reduced calcium flux by preventing the release of calcium from intracellular stores (248) . These data demonstrate the importance in CD22 in the negative regulation of receptor activity (249, 250, 251, 252) . Also upon receptor activation, separate tyrosine residues become phosphorylated, creating binding sites for Lyn, Syk, Shc, PI3K, PLCγ, and Grb2 (245). Poe et al. (245) predict that the recruitment of Shc and Grb2 to the phosphorylated CD22 facilitates the binding of SHIP (Src homology 2-containing inositol phosphatase) as part of a CD22/Grb2/Shc/SHIP quaternary complex. The formation of this complex would position SHIP at the plasma membrane, which is considered to be critical for SHIP functional activity (245) . At the cell membrane, SHIP is able to reduce the production of IP3, ultimately resulting in a decrease of extracellular calcium influx (248, 253) . CD22-deficient mice display reduced proliferation responses and decreased overall tyrosine phosphorylation in response to BCR engagement (254, 255, 256, 257, 258) . These mice also showed an increase in intracellular calcium concentrations (259, 260, 261) , but no activation of the JNK pathway. Based on these data, CD22 is positioned to both transduce signals from activated tyrosine kinases to downstream effector molecules, and regulate calcium mobilization from both intracellular and extracellular sources.
FcγRIIb also mediates its inhibitory effects on BCR activation through interaction with SHIP (243, 244) . SHIP is recruited to the phosphorylated ITIM in the cytoplasmic domain of FcγRIIb, where the phosphatase is able to catalyze the hydrolysis of PIP3 to PIP2. As Akt and PLC-gamma require PIP3 for proper enzymatic function, FcγRIIb is capable of attenuating BCR-mediated signaling by effectively altering the pool of available phosphoinositides (262,263,264). (206) . BLNK (also known as SLP-65 and BASH) is thought to be the B cell equivalent of SLP-76, sharing a 33% sequence homology and related domain structures (206) . Like SLP-76, BLNK contains several phosphorylated tyrosine residues, a central proline rich region, and a carboxy-terminal SH2 domain (201) . Upon BCR stimulation, BLNK is recruited to the membrane by an unknown mechanism, allowing the SH2 domain of BLNK to interact with Syk, resulting in BLNK phosphorylation. This effectively creates SH2-binding sites for Btk, Grb2, Vav, Shc, Nck, and PLC-gamma2. Both Btk and Syk are necessary for the activation of PLCgamma and subsequent calcium flux, and BLNK appears to be a link between upstream Btk and Syk kinase signaling and downstream effects on calcium mobilization. The interaction between PLC-gamma and BLNK also facilitates the activation of transcription factor NF-kappaB (265), which in turn activates genes involved in promoting cell survival. This interaction is supported by the finding that BLNK inactivation led to a signaling defect in the NFkappaB pathway (265) .
BLNK
Several studies have determined the importance of BLNK in BCR-mediated signaling. The BLNK-/-DT40 cell line cannot increase intracellular calcium concentrations or activate the Erk, JNK, or p38 signaling pathways (266) . However, transfection of wild-type BLNK into this cell line restored BLNK-mediated downstream effects. Additionally, overexpression of a mutant of BLNK that can not be phosphorylated on four of its tyrosine residues, thus preventing PLCγ binding, results in the dominant inhibition of BCR-stimulated PLC-gamma activation, calcium mobilization, and NF-AT activity (267). Pappu et al. (268) created a BLNK-deficient mouse model to examine the in vivo role of BLNK in B cells. B cell development in these mice was blocked at an early stage (from B220+CD43+ to B220+CD43-) and only a small percentage of B cells were detected in the periphery. Overall, the phenotype of these mice resembles that of xid (X-linked immunodeficiency) or Btk-/-mice (269), indicating that these two proteins function in the same signaling pathways. These results indicate that BLNK, unlike SLP-76 in T cells, is not essential for B cell development. However, BLNK does appear to be a necessary adaptor protein in BCRmediated signaling, functioning as a scaffolding protein for the establishment of signaling complexes essential in calcium regulation and activation of the MAPK pathways.
TYROSINE PHOSPHORYLATION REGULATES ADAPTOR PROTEINS THAT PLAY A ROLE IN SIGNALING CASCADES IN B AND T LYMPHOCYTES
There is mounting evidence that highly regulated mechanisms are involved in restricting the intensity and the duration of signaling through the BCR and TCR (270, 271, 272, 273, 274, 275) . Several adaptor proteins have been identified as regulators of immune cell signaling, as listed in Table 3 . Among these are Dok family proteins, CBP/PAG, and SOCS/JAB.
Dok
The Dok family of proteins (downstream of tyrosine kinases) comprises p62dok (Dok-1), Dok-R/Dok-2, Dok-3, Dok-4, and Dok-5 (276, 277, 278) . The Dok proteins contain a PH domain, PTB domain, and numerous sites for tyrosine phosphorylation (279, 280, 281) , and these proteins are found in various hematopoietic cells, including B cells and macrophages (277) . Upon immunoreceptor or growth factor receptor stimulation, Dok becomes tyrosine phosphorylated on several tyrosine residues by Abl, Tek, and Lyn tyrosine kinases, facilitating the binding of Tec kinase (in B cells), RasGAP and Nck via SH2 binding to the phosphorylated tyrosines in Dok (279, 280, 282, 283) . Subsequent downstream binding partners are specific to individual Dok family members. It has been suggested that the interaction of Dok-1 with Ras-GAP results in the inhibition of Ras activation (284), and Kashige et al. (285) reported that Dok-1 binding to RasGAP negatively regulated its GTPase activity in vitro. However, effects of Dok-1 on MAPK signaling are unknown, as several other proteins involved in the activation of MAPK are also activated upon immune cell receptor stimulation. Dok-1 has also been shown to bind to RasGAP after FcγRIIb/BCR coaggregation, and Dok-1/RasGAP complex formation is dependent upon the recruitment and tyrosine phosphorylation of SHIP (286) . SHIP is thought to act as an adaptor protein, linking Dok with Fc-gammaRIIb (286). Dok-3, which is highly expressed in B cells and myeloid cells, but not T cells (277) , does not interact with RasGAP as is observed with Dok-1 and Dok-2. Instead, Dok-3 was found to interact with the protein tyrosine phosphatase SHIP and the PTK Csk subsequent to tyrosine phosphorylation. The interaction of Dok-3 with inhibitory molecules positions this protein to act as a negative regulator of BCR-mediated signaling (277) . In conclusion, the Dok family proteins represent a key down-regulator of the Ras signaling pathway (285).
PAG/Cbp
Cbp (Csk-binding protein)/PAG (phosphoprotein associated with GEMs) is a type III transmembrane adaptor protein that appears to function in the regulation of Src family tyrosine kinases though its association with the Src negative regulator Csk (287, 288) . Cbp contains a putative palmitoylation sequence, two potential SH3 binding motifs, and ten potential tyrosine phosphorylation sites. Cbp has been found to be localized in GEMs, and this facilitates interaction between the phosphorylated tyrosine residues of Cbp and the SH2 domain of Csk (287, 288) . Overexpression of Cbp in COS cells results in Src kinase suppression (287) , and Csk association was required for this suppression to occur. Also, Cbp overexpression in Jurkat cells resulted in impaired Fyn activity and reduced TCR-mediated NF-AT activation (288) .
These data suggest a model in which Cbp couples Csk to Src family members in the GEMs of resting lymphocytes (206) . Receptor activation results in the dephosphorylation of Cbp and subsequent disengagement of Csk, resulting in free activation of Src family members.
SOCS/JAB
Hematopoietic cells regulate their growth, function, and differentiation through a diverse cytokine signaling network (289) . As most cytokine receptors lack intrinsic kinase activity, ligand-dependent phosphorylation events are mediated by non-receptor tyrosine kinases (289) . The main tyrosine kinases associated with cytokine receptors are the Janus (JAK) family. Upon cytokine binding the receptors oligomerize, inducing JAK activation. The activated JAKs can in turn phosphorylate tyrosine residues in the cytokine receptor tail, leading to the recruitment and activation of other signaling molecules like STAT (signal transducers and activators of transcription) proteins. Activated STAT molecules complex and translocate to the nucleus where they activate the transcription of a variety of cytokine responsive genes. While it is known that most cytokine responses are limited in duration and magnitude, little is known about mechanisms by which cytokine signaling is regulated (289) . One family of proteins that may be involved in this process are the SOCS/JAB/CIS proteins. SOCS (suppressors of cytokine signaling) are a newly characterized family of cytokine-inducible suppressors of cytokine signaling (also called JAB -janus kinase binding protein, SSI-STAT-inducible STAT inhibitors, and CIS-cytokine-inducible SH2 protein) (290, 291, 292, 293, 294, 295, 296) . To date, there are eight members of the SOCS family (CIS and SOCS1-7), all containing a similar protein domain structure, including an N-terminal variable region, a central SH2 domain, and a Cterminal SOCS-box motif (290, 291, 292, 293, 294, 295, 296) . SOCS1 (JAB/SSI-1) and SOCS3 are both involved in the inhibition of the Jak/STAT pathway of various cytokines (297) , while SOCS2 appears to counteract the inhibitory actions of SOCS1 (298, 299) . CIS has been identified as a specific inhibitor of STAT5 signaling, while the functions associated with SOCS4-7 have yet to be identified (300, 301) . The expression of SOCS proteins appears to be regulated by cytokine signaling, as SOCS-1 mRNA was found to be increased upon cytokine stimulation (291, 293) . Additionally, IFN-gamma and, to a lesser extent, IL-6 have been shown to induce SOCS protein expression (302) . This presents a fascinating negative feedback loop in which the ability of SOCS to down-regulate cytokine signaling is dependent upon signaling through that particular cytokine.
CIS was first identified by Yoshimura (290) as an immediate early gene induced in response to signaling by IL-2, IL-3 and EPO. Overexpression of CIS can partially suppress IL-3 and EPO-induced proliferation, as well as STAT5 activation (290, 300) . CIS1 was found to specifically bind to the phosphorylated tyrosine residue at position 401 of the EPO receptor, a major site of binding for STAT5 (303) . Therefore, CIS1 may function to inhibit cytokine signaling by competing with STAT5 for binding sites on the activated receptor (289) . Another possibility is that CIS1, by virtue of its binding domains, functions as an adaptor protein, linking negative signaling molecules to the activated receptor. Matsumoto (301) generated transgenic mice expressing the CIS gene under control of the beta-actin promoter. These mice developed normally, though their body size and weight was decreased with respect to wild type mice, indicating a defect in hormone signaling. Female transgenic mice showed defects in the development of their mammary glands. Also, IL-2-induced activation of STAT5 was inhibited in T cells of these transgenic mice, while leukemia inhibitory factor (LIF)-induced STAT3 activation was not affected. These phenotypes resemble the phenotype of STAT5a and STAT5b knockout mice (304, 305, 306, 307, 308) . These data suggest a role for CIS1 in the negative regulation of STAT5 mediated signaling pathways.
JAB/SOCS1/SSI-1 (herein referred to as SOCS1) was first identified as an inhibitor of IL-6-induced differentiation of murine monocytic leukemic M1 cells, a JAK binding protein, and also as a protein with an SH2 domain similar to that of STAT proteins (292, 293, 291) . In fact, SOCS1 has been shown to bind to all four JAKs proteins via its SH2 domain, and to inhibit JAK kinase activity in vitro. Overexpression of SOCS1 results in the inhibition of any signaling pathway utilizing the JAK kinases, including STAT5 activation by EPO receptor, STAT3 activation by LIF or IL-6, and c-fos induction by IL-2 (302). The mechanism by which SOCS regulates JAK activation is similar to CIS/STAT5 regulation. The SOCS1-SH2 domain binds to the Y1007 in JAK2, a critical tyrosine residue within the activation loop of the JAK2 kinase domain (309) . Based on extensive mutational analysis, it was determine that the interaction with JAK2 also requires an additional N-terminal 12 amino acid region (the kinase inhibitory region, KIR) (302). Thus, SOCS1 appears to play an essential role in the down-regulation of cytokine signaling by inhibiting JAKs activation.
Recently, SOCS1-/-knockout mice were developed (310, 311, 312) . These mice displayed severe growth retardation and died within three weeks after birth. Fatty degeneration of the liver was observed, as well as monocytic infiltration of several organs. Lymphocytes in the thymus and spleen were decreased in comparison to wild type lymphocytes, and showed accelerated apoptosis with age.
These phenotypes suggest that SOCS-1 is required for the in vivo regulation of several cell types, and is essential for normal postnatal growth and survival (302).
SERINE/THREONINE PHOSPHORYLATION OF ADAPTOR PROTEINS
Phosphorylation of proteins is a reversible form of posttranslational modification that occurs rapidly in response to cellular signals to regulate protein function. Phosphorylated proteins often display conformational changes and/or altered ability to interact with binding partners. Until recently tyrosine phosphorylation regulated protein-protein interactions were the subject of thorough investigation while the sole consequence of serine/threonine phosphorylation were thought to be allosteric modifications. In the past few years it became apparent that serine/threonine phosphorylation regulates protein-protein interactions not only via allosteric mechanism, but also results in their ability to form complexes with phospho-serine/threonine specific binding partners. Four phospho-serine/threonine binding domains that have been identified are described below.
14-3-3 ligand binding groove was the first phosphoserine/threonine specific binding domain to be identified (313) . It represents a carboxy-terminal part of the 14-3-3 molecule with highly conserved residues lining the inner surface of a concave ligand-binding groove (314) . Co-crystallization studies have confirmed the phosphorylation specific nature of 14-3-3-ligand interactions (315) . Most well-known consensus sequences for 14-3-3 conserved binding groove are RSXpS/TXP and RXSXpS/TXP. Arginine in -3 or -4 position relative to phosphorylated serine or threonine is required, whereas serine in -2 and proline in +2 are preferable. Serine or threonine in position 0 must be phosphorylated for 14-3-3 to bind to a target protein. Phosphorylation of serine in -2 position does not enable 14-3-3 binding (316). 14-3-3 binds to a variety of signaling and structural proteins, thus it may act as a scaffold to bring different target proteins into complexes facilitated by its ability to form saddle-shaped dimers via interaction between amino terminal parts of the two 14-3-3 molecules (314).
WW domains are relatively small 35-40 amino acid modules that bind proline-rich sequences PPXY or PPLP. Recently it became apparent that certain WW domains bind target proteins in a phosphorylation specific manner. WW domains of prolyl isomerase Pin1 and ubiquitin ligase Nedd4 have been shown to recognize pSer/Thr-Pro motifs on target proteins (317) . Pin1 is a prolyl isomerase, a protein whose function is cis-trans isomerization of peptidyl-prolyl bond. Pin 1 differs from other prolyl isomerases as it is able to catalyze isomerization of pSer/Thr-Pro bond while it is known that phosphorylation of Ser or Thr residue in Ser/Thr-Pro sequences reduces the rate of isomerization for other prolyl isomerases (318) . WW domain of Pin 1 binds mitotic phosphoproteins via interactions with p-Ser or p-Thr. This binding occurs in a phosphorylation dependent manner, since Pin 1 does not initiate binding to mitotic targets if they were dephosphorylated. The crystal structure shows that the Pin 1 WW domain has a hydrophobic cluster formed by different strands of beta sheets (318) . Co-crystallization of the WW domain of Pin 1 with a phosphopeptide substrate shows the structural basis for WW-phosphorylated target interactions (319) . WW domain of ubiquitin ligase Nedd4 has also been shown to associate with target proteins via phosphothreonine or phosphoserine interactions, which are responsible for presentation of proteins for ubiquitination (318, 317) .
Forkhead associated domains (FHA) are conserved 55-75 amino acid modules that were originally found in forkhead family transcription factors (320) . They are present in both eukaryotes and prokaryotes. FHA domain contains three highly conserved stretches of amino acid separated by variable regions. Each conserved stretch contains invariable residues in the middle of it -a Gly for the first and third, His for the second position. The secondary structure of FHA has a beta strand structure. The majority of FHA proteins known today are nuclear proteins that fall into three categoriestranscription factors, DNA repair proteins or cell cycle proteins. Yeast FHA containing DNA repair protein Rad53p is the best studied. It has two FHA domains, FHA1 and FHA2, both of which bind to target proteins in a phosphorylation dependent manner, specifically recognizing phospho-threonine (321, 322) . The FHA1 domain binds phosphothreoninecontaining sequences within the consensus pTXXD, whereas FHA2 binds pTXXI (323, 324) . Other FHA containing proteins display different preferences for amino acid in the +3 position though it is clear that their binding to target proteins is phospho-threonine specific. Liao and co-workers have shown that the FHA2 domain of Rad53p can also bind phosphotyrosine containing targets (321) . Their data suggest that FHA domains may be dual specificity binding modules.
WD 40 motifs were originally discovered in the beta subunit of heterotrimeric G proteins (325). Since then they have been found in various other proteins. WD 40 motifs represent regions of approximately forty amino acids. Their characteristic feature is that they always terminate with TrpAsp (WD). WD-40 motifs are always arranged in tandem with sequence similarity among them. In the past few years a number of reports indicated that WD-40 motifs of F-box containing proteins bind their target proteins in a serine/threonine phosphorylation-dependent manner (317) . Fbox proteins are the ones responsible for recognizing phosphorylated substrates and linking them to E3 ubiquitin ligases. The biochemical data accumulated on F-box-protein interactions with their substrates suggests that it is WD-40 repeat regions of F-box proteins that mediate F-box protein binding to the substrate (326, 327, 328, 329) . Unlike for 14-3-3, WW and FHA domains, for WD-40 domains no experiment has been performed to provide us with structural proof that WD-40 indeed binds substrates in phospho-serine/threonine dependent manner.
DIRECT EFFECTS: SERINE/THREONINE PHOSPHORYLATION OF AN ADAPTOR PROTEIN RECRUITS IN A BINDING PARTNER FOR IT.
Paxillin
Paxillin was initially discovered as a tyrosine phosphorylated protein from Src transformed cells (330) . Paxillin is localized to focal adhesions, where it serves as a scaffold for a wide variety of signaling and structural proteins. The ability of paxillin to bind various proteins is attributed to several protein-protein interaction domainsi.e., LD motifs and SH2 and SH3 binding motifs in the amino terminus and four LIM domains in the carboxy terminus. LD motifs are conserved eight amino acid leucine rich sequences (LDXLLXXL), serving as binding sites for a number of paxillin binding partners such as FAK, vinculin, and PYK2. LIM domains are double zinc finger motifs approximately 50 amino acids long whose function is to serve as protein-protein binding modules. LIM domains of paxillin promote its localization to the plasma membrane via association with integrins. Paxillin is crucial for embryogenesis since paxillin knockout mice die on the seventh-eighth day of embryogenesis (160) . Paxillin deficient cells display an inability to spread (161) .
Tyrosine phosphorylation of paxillin and its functional significance has been extensively studied for some time, while serine/threonine phosphorylation has started to draw attention only recently. Paxillin is phosphorylated on serine residues in vivo in response to plating of cultured cells on vitronectin or fibronectin, and also in mitosis and in MCF-7 cells in response to heregulin stimulation (331, 332, 333, 334) . The identity of serine/threonine kinases that phosphorylate paxillin in vivo is unknown although it is known that paxillin is serine phosphorylated in response to PKC activation following PMA treatment and treatment with a PKC inhibitor reduces paxillin serine phosphorylation (331) . The fact that paxillin is phosphorylated upon adhesion of cells to ECM was confirmed by (335) . Their work is cell type specific for EL4 cells, which represent murine thymoma cell line. These cells display an ability to adhere in response to PMA treatment. PMA treatment also results in serine phosphorylation of paxillin. The signaling cascade may proceed from PMA stimulation via MEK/ERK pathway to adhesion. If a specific inhibitor of MEK activation is added, there is a reduction in a number of adherent cells. ERK is one (though not only) kinase that is activated downstream of PKC in these cells. MEK/ERK inhibitor abolished PMA induced paxillin phosphorylation leading to the suggestion that it proceeds from PKC via MEK/ERK pathway to paxillin. Paxillin is a substrate for ERK2 in vitro (335) . Recent data of Hashimoto and co-workers indicate that paxillin associates with PAK3 and serves as a substrate for this kinase in vitro (336) .
Paxillin has four LIM domains in its carboxy terminus. GST-LIM2 and GST-LIM3 constructs were phosphorylated on threonine or serine, respectively, in vitro (whereas GST-LIM1 and GST-LIM4 were not). Site directed mutagenesis was employed to identify phosphorylation sites within LIM2 and LIM3 domains. LIM3 and LIM2 become phosphorylated during cell adhesion to fibronectin in vivo. Phosphorylations of LIM domains of paxillin promote localization of this protein to focal adhesions. Certain sitedirected mutants of paxillin, which have serine or threonine mutated to alanine or valine, respectively, do not localize to focal adhesions as efficiently as a wild type, and as a result these cells adhere to fibronectin poorly. Serine/threonine phosphorylations of LIM domains bring paxillin to newly created focal adhesions (337) .
Serine/threonine phosphorylation of paxillin also has a role in cell movement, which was described in a paper by Vadlamudi and colleagues (334) . They found that invasiveness of MCF-7 cells is increased in response to heregulin exposure. Along with this, in response to heregulin treatment paxillin becomes phosphorylated on serine and threonine residues (334) as demonstrated by SDS-PAGE mobility shift, phosphoamino acid analysis and serine/threonine phosphatase versus tyrosine phosphatase treatments; the latter does not interfere with heregulin induced phosphorylation of paxillin (334) . This group of researchers found that two pools of paxillin are present in MCF-7 cells: one of them is co-localized with focal adhesions, while the other is cytoplasmic. Heregulin treatment causes relocation of paxillin from focal adhesions to perinuclear areas of the cytoplasm accompanied by changes in cell shape. Serine/threonine phosphorylation of paxillin and accompanying cell scattering are dependent upon p38MAPK rather than p42/44MAPK pathway activation, which has been demonstrated by use of specific MEK inhibitors. Overall, these data indicate that heregulin treatment leads to paxillin relocation from focal adhesions that promotes disassembly of the latter, which is necessary for cell movement to occur (334).
Gab1
The name Gab1 stands for Grb2 associated binder 1. In response to insulin, cytokine or growth factor stimulation (HGF, EGF, NGF, PDGF) Gab1 becomes phosphorylated on tyrosine and binds the tyrosinephosphorylated receptor directly, or indirectly via Grb2 in a phosphorylation dependent manner (338) . Gab1 has an amino terminal PH domain that tethers Gab1 at the membrane via PIP3 interaction and carboxy terminal Met binding domain (MBD) that mediates direct interaction of Gab1 with c-Met, and also has binding sites via which it interacts with SH3 domain of Grb2. There are 21 tyrosine residues in between these two regions, which upon phosphorylation serve as docking sites for a number of binding partners. The list of Gab1 binding partners includes Grb2, cMet, p85 subunit of PI3K, PLC-gamma, Shc, Shp2 phosphatase, Crk and CrkL (339, 340, 338) .
Phosphoamino acid analysis of Gab1 overexpressed with dominant negative or activated MEK shows that serine/threonine phosphorylation levels of Gab1 are elevated in response to co-expression with constantly active MEK. Gab1 binds phosphorylated ERK2 directly and phosphorylated by it; Gab1 also associates with phospho-Erk1 in response to MEK activation (341) . Several years later this same group of authors followed with another report, which demonstrates that c-Met activation results in MAPK cascade activation, and Gab1 becomes phosphorylated by active ERK2 followed by recruitment of PI3K to the membrane (339) . Consequently, Akt activation follows in response to PI3K activation as a result of an association with Gab1. They state that Gab1 has to be phosphorylated both on threonine and tyrosine residues to ensure for PI3K association (339) .
Okadaic acid treatment of cultured cells results in serine/threonine phosphorylation of Gab1 (342) . One of the effects of c-Met stimulation by HGF is cell scattering, which is the result of c-Met stimulated increased cell motility. Okadaic acid treatment of cultured cells prior to HGF stimulation prevents cell scattering. Under these conditions Gab1 is found to be hyper-phosphorylated on serine and threonine residues and hypo-phosphorylated on tyrosine residues. The okadaic acid-promoted decrease in tyrosine phosphorylation of Gab1 is a consequence of its elevated serine/threonine phosphorylation which by some undetermined mechanism prevents c-Met from interacting with and phosphorylating Gab1 (342) .
Serine/threonine phosphorylation results in Gab1 association with 14-3-3. The functional significance of this interaction remains to be determined, as it does not seem to interfere with Gab1/Met1 interactions and therefore sequester Gab1 from the membrane.
Okadaic acid activates MAPK and PKC by inhibition of serine/threonine phosphatases. Using pharmacological agents that are known to be specific inhibitors of MAPK pathway or PKC kinase, they show that for serine/threonine phosphorylation of Gab1 in response to okadaic acid treatment is PKC dependent. Phorbol ester treatment results in a decrease of both electrophoretic mobility and tyrosine phosphorylation levels of Gab1. Gab1 is a substrate for conventional PKC isozymes in vitro. PKC inhibitor staurosporine treatment restores cell scattering inhibited by okadaic acid (342) . The authors hypothesize that serine/threonine phosphorylation alters Gab1 conformation so that tyrosine residues cannot be presented for phosphorylation; as a consequence, the docking sites for binding partners are not being created which results in Gab1 inability to associate with them (342).
PECAM-1
Platelet endothelial cell adhesion molecule 1 (PECAM-1) is a transmembrane glycoprotein belonging to immunoglobulin family of adhesion molecules that is expressed only in hematopoietic and vascular cells. Upon phosphorylation of tyrosines within its ITAM motif it becomes a binding partner for PI3K, PLC-gamma, SHP1 and 2, Stat5a, and cell-cell junction proteins catenins beta and gamma (343, 344, 345) . PECAM-1 is phosphorylated not only on tyrosine but also on serine and threonine residues. The levels of serine/threonine phosphorylation of PECAM-1 are elevated in response to LPS treatment of monocytes in a PKC dependent manner, which is demonstrated by the observation that PKC inhibitor treatment down regulates LPS induced serine/threonine phosphorylation of PECAM-1 (346) . Along with PECAM-1 serine/threonine phosphorylation LPS induces transendothelial migration of monocytes. Phosphorylation of PECAM-1 on serine and threonine residues appears to be connected to cell migration, this conclusion comes from the fact that PKC inhibitor treatment blocks monocyte migration through the endothelial cell layer (346) . Phosphatase inhibitor treatment up-regulates both PECAM-1 serine/threonine phosphorylation and transendothelial movement of monocytes. These data suggests that PECAM-1 may be involved in the regulation of monocyte movement (346) .
PECAM-1 is able to associate with both beta and gamma catenins (343) . Serine/threonine phosphorylation of PECAM-1 has been shown to down regulate its ability to associate with gamma catenin (344) . PECAM1 is a substrate for PKC in vitro and phosphorylated on serine/threonine residues in response to PKC activation in vivo (344) . In response to PKC activation by DAG a decrease in PECAM-1 interaction with gamma catenin is observed, whereas PKC inhibitor bisindolylmaleimide treatment promotes this interaction. PKC, therefore, may be the kinase responsible for serine/threonine phosphorylation of PECAM-1 in vivo and PKC dependent serine/threonine phosphorylation of PECAM-1 may be a mechanism of regulation PECAM-1/gamma catenin interactions. Experiments of Ilan and colleagues suggest that one of the functions of PECAM-1 may be to bring catenins to adherence junctions (344); PECAM-1 interaction with gamma catenin is thought to link PECAM-1 to the cytoskeleton via vimentin and therefore participate in transduction of signals that regulate cell migration (344).
Sos
In response to growth factor stimulation receptor tyrosine kinases will autophosphorylate on tyrosine residues, creating binding sites for the adaptor proteins Grb2 and Shc. They, in turn, recruit a protein named Son of sevenless (Sos) to the membrane. Sos protein is a guanine nucleotide exchange factor for Ras. Once at the membrane, Sos promotes GDP to GTP exchange on Ras, activating it. Sos links growth factor receptor activation to Ras stimulation (347). It was determined several years ago that Sos1 is phosphorylated in response to EGFR stimulation (348) . Phosphoamino acid analysis determined that Sos is phosphorylated predominantly on serine and to the lesser extent on threonine residues, while no tyrosine phosphorylation was detected (349) . It was observed that the C terminus of Sos contains potential sites for MAPK phosphorylation. Indeed, using phosphotryptic-mapping analysis it was demonstrated that Sos is a substrate for MAP kinase both in vitro and in vivo, and the sites of phosphorylation were identified (350, 351) . Since it has been determined that Sos protein is serine/threonine phosphorylated, researchers have been trying to elucidate the functional significance of Sos phosphorylation. Rozakis-Adcock and co-workers demonstrated that serine/threonine phosphorylation of Sos down regulates Sos-Grb2 association with EGFR and Shc although does not affect Sos interaction with GST-fused Grb2 (349). Corbalan-Garcia and colleagues discovered that in response to being phosphorylated Sos dissociates from Grb2. The data accumulated by the two groups must be somewhat controversial, which might be explained by the differences in experimental setup and also by the fact that these groups of authors used Sos from different species (either human or murine) in their experiments. Both groups agree that MAPK dependent Sos phosphorylation serves as a feedback mechanism of Ras/MAPK pathway regulation. Sos is phosphorylated in MAPK cascade dependent manner by active MAP kinase and supposedly by other serine/threonine kinases that are activated downstream of MAPK pathway (349, 350) .
In T cells the MAPK cascade is activated in response to TCR ligation. Both TCR activation and PMA stimulation result in serine/threonine phosphorylation of Sos-1; this is demonstrated by reduced mobility of Sos-1 derived from PMA stimulated cells (352) . The mobility shift is lost if phosphatase treatment has been applied to Sos-1 from PMA treated cells. In T cells serine/threonine phosphorylation of Sos-1 is not MAPK cascade dependent, this conclusion comes from the observation that MEK inhibitor treatment does not result in decrease in serine/threonine phosphorylation levels of Sos-1 promoted by TCR engagement. Mutation of seven potential MAPK consensus sites does not diminish ability of Sos-1 to be phosphorylated on serine/threonine residues either (352) .
It is well known that prolonged exposure to PMA results in depletion of cellular pool of PKC due to its subsequent ubiquitination (353, 354) . When cells that had undergone 16-hour PMA treatment were subjected to TCR stimulation no serine/threonine phosphorylation of Sos was detected. The same result was observed in cultured cells pre-treated with specific PKC inhibitors (352) . Therefore, PKC may be a Sos kinase in vivo. Phosphorylation of Sos did not lead to its uncoupling from Grb2 under described conditions, which is in agreement with previous data of Rozakis-Acock and co-workers. Zhao and colleagues did not attempt to clarify the functional significance of Sos phosphorylation (352).
Cbl
c-Cbl is an adaptor protein that is ubiquitously expressed and known to be phosphorylated on tyrosine residues (102). Cbl has several modular domains including a zinc ring finger motif, SH2 and SH3 binding motifs and leucine zipper motif. These modules facilitate the association of Cbl with 40 target proteins, among which are receptor and non-receptor tyrosine kinases, E2 ubiquitination enzyme, p85 subunit of PI3 kinase, and adaptor proteins such as Grb2, Nck, and Crk. Cbl has the ability to form dimers via its carboxy-terminal leucine zipper motif. T cell receptor activation leads to tyrosine phosphorylation of Cbl and its transient association with CrkL and the p85 subunit of PI3K (355, 102) . P85 binds Cbl directly but it cannot bind CrkL, unless it associated with Cbl that brings it into a close proximity with CrkL. Cbl has to be tyrosine phosphorylated to perform this function. Cbl, therefore, act as a scaffold that brings PI3K and CrkL together (355).
Liu and co-workers found that TCR ligation leads to serine/threonine phosphorylation of Cbl upon which Cbl becomes associated with 14-3-3 (356) . Cbl interaction with 14-3-3 is direct and occurs only in response to TCR (356) or CD43 (357) ligation; while in unstimulated cells there is no Cbl-14-3-3 complex detected. 14-3-3 displaces PI3K from Cbl. Serine/threonine phosphorylation of Cbl has also been shown to down regulate its tyrosine phosphorylation and association with another partner, the adaptor protein CrkL (356) . PMA treatment promotes serine/threonine phosphorylation of Cbl and its consequent association with 14-3-3. Pretreatment of cells with specific PKC inhibitors prior to PMA treatment results in an inability of PMA to induce serine/threonine phosphorylation of Cbl. Cumulatively, these data suggest that Cbl phosphorylation may be PKC dependent (358, 355, 357) . PMA treatment also results in a decrease in tyrosine phosphorylation levels of Cbl and therefore promotes its dissociation from p85 and CrkL. Recent work of Pedraza-Alva and co-workers shows that CD43 receptor cross-linking causes Cbl association with Vav and PI3K; the latter is activated in response to this interaction event (357). It is noteworthy that Cbl does not have to be phosphorylated on tyrosine residues for described CD43 induced interactions to occur, as there is no tyrosine phosphorylation of Cbl detectable under those conditions. Pedraza-Alva and colleagues attempted to gain an insight into the functional significance of serine/threonine phosphorylation of Cbl (357). It has been known for some time that overexpression of Cbl has an inhibitory effect on receptor-mediated MAP kinase activation. PKC dependent phosphorylation of Cbl followed by its association with 14-3-3 is thought to block the negative effect of Cbl on MAP kinase cascade activation (357). Serine/threonine phosphorylation of Cbl also negatively regulates Cbl tyrosine phosphorylation and therefore hampers its interaction with PI3K, CrkL and other phosphotyrosine binding partners. All the data on Cbl serine/threonine phosphorylation is T cell specific. Cumulatively, it leads to the conclusion that adaptor protein Cbl is phosphorylated on tyrosine and serine/threonine via two separate receptor-signaling pathways. Phosphorylation on either tyrosine or serine/threonine residues may enable Cbl to associate with different set of binding partners and therefore be engaged in either one of the two signaling cascades descending from the T cell receptor.
IRS1
Insulin receptor substrate 1 is a 165-185 kDa protein that associates with SH2 containing proteins in a phosphorylation dependent manner.
IRS1 becomes phosphorylated on tyrosine residues by insulin receptor and consequently associates with PI3 kinase, activating the latter. PI3 kinase activation results in activation of Akt/PKB, which sends the signal further downstream. The physiological consequences of insulin receptor signaling are glucose uptake and glycogen synthesis. In response to PDGF (in a PI3K/Akt dependent manner) (359, 360) or endothelin-1 (in a PKC and MAPK dependent manner) (360) stimulation IRS1 becomes phosphorylated on serine residues, four of which are MAPK consensus sites (361) . Serine phosphorylation of IRS1 leads to the decrease in its tyrosine phosphorylation levels (359, 360) and IRS1/PI3K complex disengagement (360,362) therefore inhibiting insulin receptor signaling. PDGR receptor stimulation results in inhibition of insulin receptor signaling, cased by inability of IRS-1 to be tyrosine phosphorylated and form a complex with PI3K. The IRS1 mutant, which has four serine residues substituted by alanines, retains the ability to be tyrosine phosphorylated in response to insulin treatment in the presence of PDGFR stimulation and associate with PI3K, activating it. In response to Akt activation IRS1 association with PI3K is abrogated. It is not known yet whether Akt phosphorylates IRS-1 directly or simply promotes IRS-1 phosphorylation by activating serine/threonine kinase(s) downstream of it (360) . Whatever the mechanism might be, attenuation of insulinreceptor signaling by active Akt suggests a model for negative feedback loop where PI3 kinase, activated in response to insulin-receptor stimulation via IRS-1 interaction, in turn activates Akt, which comes along and phosphorylates IRS-1 causing dissociation of IRS-1/PI3K complex (360).
Ogihara and colleagues (363) and Staubs and coworkers (359) observe serine/threonine phosphorylation of IRS1 in response to PI3K association promoted by insulin receptor activation. IRS1 is a substrate for PI3K in vitro (364, 365) . These data suggests that PI3 kinase itself may be responsible for an attenuation of insulin receptor signaling. Ogihara and co-workers also suggest that serine phosphorylation of IRS1 may lead to presentation of phosphotyrosines for tyrosine phosphatases therefore enabling attenuation of insulin signaling (363) .
Decrease in tyrosine phosphorylation of IRS1 was also observed in response to PMA treatment of cultured cells (366) . Activation of endogenous PKC by phorbol ester treatment inhibits insulin receptor-mediated tyrosine phosphorylation of IRS-1. It has not been demonstrated whether IRS1 is a substrate for PKC either in vitro or in vivo (366) .
PKC is known to activate ERK1/2 in response to its activation. IRS1 is a substrate for ERK1/2 in vitro (367) . IRS1 contains four potential MAPK sites of a consensus PXS/TP. PKC activates ERK1/2 in Raf-1 dependent manner. Both ERK1/2 and Raf activation result in decreased insulin receptor mediated tyrosine phosphorylation of IRS1 in vivo, resulting in diminished IRS1/PI3K association (367).
Both insulin and PDGF receptor activation lead to PI3 kinase activation by different mechanisms, which are responsible for different outcomes. IRS-1 is a key player in insulin receptor signaling as it activates PI3K via association with it and thereby triggers insulin-receptor mediated physiological events. PDGF receptor activates PI3 kinase via another pathway and causes PI3K dependent serine/threonine phosphorylation of IRS-1, interfering with insulin receptor signaling. Serine/threonine phosphorylation of IRS-1 was observed in response to activation of insulin receptor, which is in agreement with the statement that serine/threonine phosphorylation of IRS-1 may provide the means for a negative feedback regulation of insulin receptor signaling.
pShc66
Shc is a ubiquitously expressed adaptor protein, which plays an important role in growth factor receptor signaling. Upon tyrosine phosphorylation by ligandactivated receptor tyrosine kinases Shc becomes a docking molecule for Grb2 allowing Grb2 to bring Ras-GTP Sos to the membrane. Three isoforms of Shc are known -two of them, p46 Shc and p52 Shc are synthesized from the same transcript (starting sites differ), whereas p66 Shc is a result of alternative splicing (368, 53) . The three members of Shc family may have different biological functions (56, 53) . p66 Shc, for example, plays a role in regulation of oxidative stress response and life span in mice (369) . Shc66 knockout mice have a prolonged life span and increased resistance to oxidative stress (369) . p46 Shc and p52 Shc cannot substitute for the p66 defect in p66Shc-deficient mice. Oxidative stress response mediated by p66 Shc is serine phosphorylation dependent, which is demonstrated by the fact that non-phosphorylated p66Shc cannot revert mice to a normal phenotype (369) . EGFR stimulation results in both tyrosine and serine/threonine phosphorylation of the p66Shc isoform in CHO cells, which is demonstrated by a mobility shift characteristic of serine/threonine phosphorylation. Moreover, p66Shc has to be phosphorylated on tyrosine prior to serine/threonine phosphorylation. Serine/threonine phosphorylation of p66Shc is MAPK cascade dependent, although the identity of the kinase is unknown. Upon serine/threonine phosphorylation the ability of p66Shc to bind EGFR is abolished, although it is still able to associate with Grb2. p66Shc competes with p52Shc for Grb2 as the amount of Grb2 in cells is limiting. Therefore, in response to serine/threonine phosphorylation p66Shc carries Grb2 away from the EGFR. Overexpression of p66 Shc inhibits ERK activation (370) . These data suggest the existence of a negative feedback regulation of EGFR signaling. EGFR ligation leads to engagement of Shc/Grb2/Sos complex via which activation of Ras/Raf/MEK/ERK cascade occurs. Serine/threonine phosphorylation of p66Shc leads to disengagement of Shc/Grb2 complex from the EGFR leading to attenuation of the EGFR signaling (370) . In mesangial cells p66Shc is serine/threonine phosphorylated in response to endothelin-1 receptor stimulation (371) . p66 Shc serine/threonine phosphorylation occurs in response to ERK1/2 activation although the identity of kinase that phosphorylates Shc66 under these conditions is unknown. Serine phosphorylation of p66Shc brings it into proximity with three proteins two of which remain to be identified and the third is 14-3-3 (371). Function of p66Shc association with 14-3-3 remains unknown. As 14-3-3 is known to bind a wide variety of proteins, and the 14-3-3 dimer is capable of binding two different proteins at once, it may either bring p66Shc into proximity with some yet unidentified binding partner(s) for undetermined purpose or simply to sequester p66Shc from the membrane, preventing it from competing with two other Shc isoforms for Grb2 pool.
Taxol, an antitumor agent that has already been approved for treatment of breast, lung, and ovarian carcinomas, causes serine/threonine, but not tyrosine, phosphorylation of pShc66 in human lung carcinoma cells (372) . Serine/threonine phosphorylated p66Shc prevents it from interacting with Grb2. Although phosphorylation of Raf-1 and ERK1/2 is observed simultaneously with p66Shc phosphorylation, these kinases are not responsible for serine/threonine phosphorylation of pShc66. Taxol-mediated serine phosphorylation of p66Shc is protein synthesis dependent, as cycloheximide treatment inhibits taxol-induced phosphorylation of p66Shc and Raf-1. These data lead to hypothesis that taxol-inducible p66Shc activation occurs in response to stimulation of yet unknown signaling pathway, different from the MAP kinase cascade (372) .
Taxol is a microtubule-interacting agent that is capable of arresting cell in mitosis and it also has an apoptotic effect. Since the serine/threonine phosphorylation of Shc reaches maximum at 9-18 hours after treatment, when cell may be in the mitotic stage, the authors speculate that Shc66 serine/threonine phosphorylation may be responsible for transducing an apoptotic signal (372) referring to the fact that Ser→Ala substitution of p66 Shc enhances resistance to apoptosis (369). PHOSPHORYLATION OF AN ADAPTOR PROTEIN  ALTERS  ITS  CONFORMATION  AND  SUBSEQUENT FUNCTION 
DIRECT EFFECTS: SERINE/THREONINE
AFAP-110
AFAP-110 was first identified as a 110-kDa protein that co-immunoprecipitated with activated Src (373) . In normal cells AFAP-110 co-localizes with actin stress fibers and the cortical actin matrix. AFAP-110 has several protein-protein interaction modular domains such as WW domain, SH2 and SH3 binding motifs, serine threonine kinase interaction domain, pleckstrin homology (PH) domains, leucine zipper motif, and carboxy terminal actin binding domains (374) . AFAP-110 binds actin filaments directly via its carboxy-terminal actin binding sequences, and it associates with active Src via SH2/SH3 interactions. The amino-terminal PH domain of AFAP-110 has been shown to facilitate its interactions with PKC (Qian et al, manuscript in preparation). AFAP-110 therefore may serve as an adaptor protein linking signaling proteins to actin filaments.
AFAP-110 has the capability to self-associate via interactions enabled by its carboxy-terminal leucine zipper motif. In non-transformed cells it exists in multiple forms including monomers, dimers, trimers, tetramers and even larger complexes. Upon co expression with active Src, AFAP-110 is detected as dimers, but not in larger complexes. Moreover, AFAP-110 self-association is diminished. These data indicate that active Src causes a conformational change in AFAP-110 responsible for alteration in leucine zipper motif mediated self-association (375).
AFAP-110 has an intrinsic ability to remodel actin filaments as its leucine zipper mutant overexpression causes actin filament disruption in cultured cells. This ability depends upon conformational changes in this protein, which affect its multimerization status. AFAP-110 is hyperphosphorylated in Src transformed cells, not only on tyrosine but also on serine and threonine residues (376) . Recent data indicates that serine/threonine and not tyrosine phosphorylation of AFAP-110 is responsible for changes in its self-association (Baisden et al, in preparation) . AFAP-110 is a substrate for PKC in vitro and serine/threonine phosphorylated in response to PKC activation in vivo (Qian et al, in preparation) . Non-phosphorylated AFAP-110 cross-links actin filaments whereas in response to PKC phosphorylation in vitro it bundles them (Qian et al, in preparation) . Serine/threonine phosphorylation of AFAP-110 alters its function by induction of AFAP-110 transition from actin-filament cross-linking to bundling protein. The change in AFAP-110 function occurs in response to phosphorylation-dependent alteration in its conformation and therefore the ability to self-associate. Recent evidence indicates that the site for PKC phosphorylation that mediates this change exists in the serine/threonine kinase interaction domain of AFAP-110 (377) (Cherezova and Flynn, unpublished observation). PKC activation induces motility structure formation such as lamellipodia and filopodia along with disappearance of actin stress fibers. Inside of lamellipodia, actin exists as a network of bundles. AFAP-110 therefore may be involved in PKC-dependent motility structure formation, acting as a protein mediating formation of actin meshwork underlying lamellipodia once phosphorylated on serine/threonine residues in PKC dependent manner.
Cortactin
Cortactin was initially identified as a tyrosine phosphorylated substrate of active Src (151) . Cortactin has an amino terminal acidic (NTA) domain followed by a region of cortactin repeats; alpha-helical domain, proline rich motif containing tyrosines, serine and threonine residues in abundance and a carboxy-terminal SH3 domain (148) . Cortactin is localized to cortical actin structures. Recently it has been found that cortactin is involved in regulating cell motility (378). Cortactin's structure along with its localization and ability to bind actin, suggests that this protein may be positioned to link signaling events such as growth factor receptor activation to actin filament reorganization (379) . Cortactin is found to be phosphorylated in response to growth factor receptor stimuli. Phosphorylation therefore may play a role in regulation of its function (148) .
Van Damme and co-workers in 1997 have shown that in response to EGF receptor stimulation of cortactinoverexpressing human squamous carcinoma cell line p80 cortactin is converted into p85 cortactin and this conversion is a result of phosphorylation (154). Phosphoamino acid analysis has shown that EGF-induced cortactin phosphorylation occurs predominantly on serine and threonine residues. Immunofluorescence analysis indicated that upon growth factor induced phosphorylation cortactin relocates from perinuclear space to cell-matrix adhesion zone.
Campbell and colleagues show that endogenous p80 cortactin is converted into the p85 form in response to EGF stimulation, confirming van Damme and co-workers data. They also show that cortactin phosphorylation is ERK dependent since pre-treatment with the specific MEK inhibitor PD98059 abolishes EGF-induced cortactin phosphorylation. Active MEK is sufficient to cause cortactin phosphorylation but insufficient to prevent basal phosphorylation of cortactin, which suggests that there are serine/threonine kinases other than MAPK that phosphorylate cortactin in vivo. Proline-rich region has been shown to contain phosphate acceptor sites, as it can be phosphorylated by Erk when expressed on its own (380) . Although the role of serine/threonine phosphorylation of cortactin still remains to be determined, from data described above it is possible that phosphorylation of cortactin may regulate its subcellular localization. Campbell and co-workers speculate that the proline-rich domain of cortactin may interact with its own SH3 domain and therefore keep cortactin in a "closed" conformation. Serine/threonine phosphorylation of a proline-rich domain will result in abrogation of this interaction resulting in cortactin transition into the "open" conformation (380) . Alternatively, serine/threonine phosphorylation of the proline rich region of cortactin may disrupt its interaction with SH3 binding partners. The physiological significance of cortactin serine/threonine phosphorylation as well as its impact on conformation remains to be determined.
INDIRECT EFFECTS: SERINE/THREONINE PHOSPHORYLATION OF ANOTHER PROTEIN ENABLES IT TO BECOME A BINDING PARTNER FOR AN ADAPTOR PROTEIN
13.1. 14-3-3 14-3-3 proteins are small acidic proteins with a molecular weight around 30 kDa (381) . The 14-3-3 proteins are cellular components of all cells types that have been examined, and they have been found in all vertebrates, invertebrates, plants, and fungi (382, 383, 384) . The 14-3-3 family of proteins includes seven unique isoforms, named by Greek letters according to their elution order after reverse-phase high-performance liquid chromatography: beta/alpha, zeta/delta, eta, gamma, tau, sigma, and epsilon (381, 385, 386 ). 14-3-3 proteins are highly conserved among each other and across different species although they do have differences in some regions (386, 387) . All 14-3-3 proteins are able to dimerize, with the ability to form both homo-and heterodimers in vitro and in vivo (384,388). Dimerization occurs via hydrophobic interactions between highly conserved residues within amino-terminal parts of the molecules (381, 385, 386) . Carboxy-termini of two molecules brought together by dimerization create a ligand binding amphipathic groove (389, 316) . Highly conserved residues form the inner surface of the binding groove, whereas variable residues create the outer surface. This groove may bind either two different molecules or bring together different regions of the same protein therefore serving as a scaffold or allosteric regulator (389, 390) . The variant residues of the outer surface of the groove may provide specific binding surfaces for different proteins. 14-3-3 proteins bind two well-defined structural motifs on target proteins. The first contains phosphoserine in the center with arginine, serine and proline in positions -3, -2, and +2, respectively. Another one is defined as short amino acid sequence containing phosphoserine in the center with arginine, aromatic residue, basic residue and proline at positions -4, -2, -1, +2 respectively (381, 316, 391 ). 14-3-3 dimers could bind to several phosphoserine-containing motifs on one protein or bring several target proteins together as a consequence of binding to conserved motifs found on different proteins. 14-3-3 dimers also may act as molecular links between proteins bound to the conserved groove and ones associated with variable outer surface, therefore performing a role of scaffolds that regulate specific protein-protein interactions (389). 14-3-3 proteins have over 60 in vivo binding partners (314). 14-3-3 proteins have been implicated in regulation of serine/threonine kinases such Raf and PKC (382, 392, 393, 385 ). 14-3-3 proteins bind Raf and certain PKC isoforms directly and therefore serve to facilitate interactions between these signaling proteins (390). 14-3-3 brings Raf into proximity with Bcr as well (314) . Raf is a key protein kinase in mitogen activated protein kinase cascade. Raf functions downstream of growth factor receptor and Src-family non-receptor tyrosine kinases and Ras and upstream of MAP kinase to transmit developmental and proliferative signals. 14-3-3 associates with Raf in vivo regardless of Raf subcellular localization or activation status (394, 381, 395, 382) . Overexpression of 14-3-3 proteins has been shown to contribute to Raf activation, although it is clear that 14-3-3 proteins are unable to activate Raf by themselves (395) . Some other reports stated that the nature of 14-3-3 influence on Raf-1 is inhibitory (396, 397) . The data on Raf-14-3-3 interaction accumulated to date suggests the following model of Raf-14-3-3 interaction: Raf has three 14-3-3 binding sequences in its structure. 14-3-3 is bound to cytosolic Raf at aminoterminal and carboxy terminal binding sites; this association serves to keep Raf in an inactive, although activatable, state. Upon Raf activation by Ras the former undergoes translocation to the membrane. The 14-3-3 dimer is displaced from the amino terminal binding site on Raf, but it still associates with the carboxy terminal 14-3-3 binding site. Yet unidentified kinases come along and phosphorylate the serine in the center of the intermediate 14-3-3 binding site of Raf and 14-3-3 binds to it, stabilizing Raf in an active state (316, 393 ). 14-3-3 therefore has a dual role in Raf regulation, it keeps Raf in an inactive state in the cytosol, but upon Ras-dependent Raf activation it stabilizes it in an active conformation. 14-3-3 proteins also have been shown to be both PKC substrates and regulatory proteins (398, 399 ). 14-3-3 may bind to Raf and PKC at the same time, therefore bringing Raf to proximity with PKC to ensure phosphorylation of the former by the latter (381,400,390).
14-3-3 binding to a target protein often serves to keep that protein either in inactive state and/ or sequester it from binding partners. 14-3-3 binds Cdc25C phosphatase in a phosphorylation dependent manner via its RSXpSXP site -the perfect consensus for 14-3-3 binding. This interaction is responsible for keeping this protein inactive throughout G1, S and G2 phases of the cell cycle and also transports it from the nucleus to cytosol (401, 402 ). 14-3-3 bind the apoptotic protein BAD in a phosphorylation dependent fashion. The function of this interaction is to sequester BAD in the cytosol and keep it from binding to Bcl2 and also possibly protecting it from phosphatases (403). 14-3-3 binds IRS-1 and therefore prevents its association with PI3K (404).
Dubois and colleagues show that two unidentified brain kinases phosphorylate 14-3-3 on the sites located at C terminus of 14-3-3, a region where PI3K, Raf and Cbl bind to 14-3-3 (405) . Therefore, they speculate that phosphorylation regulates 14-3-3 interactions with binding partners. They also refer to the data of Aitken and colleagues that leads to suggestion that 14-3-3 alpha and delta, which are phosphoisoforms of 14-3-3 beta and zeta, respectively, may influence PKC activity more strongly than their non-phosphorylated counterparts (392) . Later that year they followed with another publication where they determined the identity of the brain kinase that phosphorylates Ser-233 of 14-3-3 as casein kinase 1 (406) . Another kinase that utilizes 14-3-3 as a substrate is sphingosine dependent protein kinase SDK1 (407). The function of 14-3-3 phosphorylation remains to be determined.
p130Cas
Crk associated substrate p130Cas was discovered over a decade ago as a phosphotyrosine-containing binding partner for active Src and Crk (408) . The Cas domain structure along with variety of binding partners, suggests that it acts as an adaptor protein. The domain structure from amino to carboxy terminus: SH3 domain, proline rich region, so-called "substrate-binding" domain that associates with adaptor proteins Crk, Nck and SHIP, serine rich motif and a carboxy-terminal region that interacts with different protein kinases and adaptor proteins (408) . Cas is involved in regulation of cell motility, cytoskeleton integrity, growth regulation, apoptosis, and Src and Crk dependent transformation (408) . Cas is localized to focal adhesions. where it associates with Crk, Src and FAK. FAK/Cas interaction occurs via proline-rich region of FAK and SH3 domain of Cas (409, 410) . Cas forms a complex with Crk at focal adhesions; Cas/Crk complexes influence cytoskeletal rearrangements in a Rac1-dependent manner (411, 408) . Focal adhesions are the sites where actin stress fibers are linked to extracellular matrix. Focal adhesions are also the sites of integrin signaling (333) .
The data accumulated so far suggests that Cas is involved in the regulation of cytoskeletal integrity, cellmatrix adhesion and cell motility. In Cas knockout cells actin filaments are disorganized but formation of focal adhesions remains intact (412) .
Cas, as well as FAK and paxillin, is phosphorylated on serine/threonine residues in mitosis and concomitantly dephosphorylated on tyrosine residues (333) . Mitosis is the stage of the cell cycle when cells display actin filament disorganization and detachment from the substratum. Mitotic phosphorylation of focal adhesion proteins must be a way of cell detachment regulation. Serine phosphorylation of Cas and FAK during mitosis promotes their dissociation from one another. Mitotic FAK is able to reassociate with interphase Cas following serine/threonine phosphatase treatment, therefore FAK/Cas interaction does not depend on tyrosine phosphorylation of FAK as serine/threonine dephosphorylated mitotic FAK has no tyrosine phosphorylation. These data indicate that serine/threonine phosphorylation of FAK and not its tyrosine phosphorylation regulates FAK/Cas complex formation (333) .
Ma and co-workers confirm that serine/threonine phosphorylation of FAK down-regulates its ability to form a complex with Cas (413) . The physiological significance of serine/threonine phosphorylation of Cas itself remains to be determined.
AP-2
Adaptor protein 2 is a multisubunit adaptor protein complex associated with endocytic clathrin coated vesicles. AP2 associates with proteins like EGF receptor substrate Eps15 and Epsin at the membrane. This association is disrupted in mitosis when both Eps15 and Epsin are phosphorylated on serine/threonine residues. Eps15 and Epsin are substrates for p34Cdc2 in vitro. Serine/threonine phosphorylation of epsin and Eps15 results in dissociation of these proteins from AP2 complex. This may provide a mechanism that inhibits clathrinmediated endocytosis in the stage of mitosis (414, 415 
Chat
Chat is a Cas/HEF-1 associated adaptor protein isolated by Sakakibara and Hattori last year (416). The function of Chat itself as well as the function of its phosphorylation has not been determined. Sakakibara and Hattori show that Chat binds the adaptor protein Cas directly, and this interaction is phosphorylationindependent (in vitro binding assay). Chat has multiple serine/threonine residues, four of which comprise potential MAPK sites (PXS/TP). Phosphorylation levels of Chat increase in response to growth factor treatment, and it is not due to tyrosine phosphorylation (there is a gel shift in response to GF treatment, but pTyr Ab does not react with the upper portion). MAP kinase may be the one responsible for GF mediated phosphorylation of Chat as MAPK inhibition results in the disappearance of the slower migrating band. Overexpression, but not phosphorylation, of Chat up-regulates JNK activity in a manner similar to that of Cas. Chat is a cytoplasmic protein, but in response to GF stimulation it moves to membrane ruffles where it colocalizes with actin (416).
NHERF
NHERF is a Na+/K+ exchange regulatory factor, which was discovered several years ago. Since then it became apparent that this is an adaptor protein. NHERF contains two PDZ domains in tandem where the majority of NHERF binding partners associate, along with the carboxyterminal region that binds ERM proteins. NHERF proteins are localized to the plasma membrane, where in addition to already mentioned function as Na+/K+ exchange regulators they also regulate transmembrane receptors and are involved into growth factor receptor signaling (417) .
In 1995, Weinman and colleagues suggested that NHERF may be a substrate for serine/threonine phosphorylation for they found potential sites for PKA phosphorylation in the C-terminus of NHERF (418) . A more recent report by Hall and co-workers shows that NHERF is constitutively phosphorylated on serine/threonine residues, and that NHERF is a binding partner and an in vitro substrate for a G protein receptor coupled kinase GRK6A (419) . The functional significance of NHERF phosphorylation remains to be determined.
NHERF proteins are able to dimerize. The physiological significance of this capability still remains to be determined. The ability of NHERF proteins to dimerize is greatly diminished in response to okadaic acid treatment. It seems therefore that protein phosphorylation might be responsible for regulation of the ability of NHERF proteins to self-associate, although it is not known at this point whether phosphorylation of NHERF themselves or NHERF binding partners influences this effect (420).
Nck/Dock
Nck is an adaptor protein that was discovered in 1990 (421) . Its domain structure suggests that it serves as an adaptor protein. Nck has three SH3 domains in tandem followed by an SH2 domain at the carboxy-terminus. Indeed, it binds a variety of target proteins such as protein kinases, adaptor and motor proteins, involved in regulation of actin filament integrity, DNA synthesis, transcription and translation as well as protein degradation (reviewed in (93)).
Two reports published in 1992 show that Nck is phosphorylated in growing cells and in response to PMA or growth factor stimulation of cultured cells (97, 96) . Phosphoamino acid analysis has demonstrated that Nck is phosphorylated predominantly on serine/threonine with one tyrosine phosphorylated peptide recovered. Neither the identity of serine/threonine kinase nor the physiological role of serine/threonine phosphorylation of Nck was determined (97,96).
Grb7
Grb7 is a 535 amino acid protein with similarity to Grb2, Shc and Nck. Grb7 family includes Grb7, Grb10 and Grb14 proteins. Grb7 proteins contain several proteinprotein interaction modules such as proline-rich, PH, Rasassociating, and SH2 in their structure, which enable them to interact with a variety of signaling proteins and therefore serve as adaptors linking receptor activation to downstream signaling pathways (422) . Grb7 is able to form homo-or heterodimers and larger complexes (423) . Dimerization of Grb7-family proteins may serve to bring signaling proteins together into large complexes. The Grb7 family of adaptors has been implicated in the regulation of cell proliferation, cell motility, apoptosis and tumorigenesis (422) .
The Grb7 family of adaptor proteins is constitutively phosphorylated on serine/threonine residues, and the level of their serine/threonine phosphorylation increases in response to EGFR and heregulin receptor stimulation (424, 425, 426) . The functional significance of this phosphorylation remains to be determined.
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